Explanatory note on general fees payable to the European Medicines Agency
The fees, fee exemptions and definitions described in this explanatory note are based on Council Regulation (EC) No 297/95 of 10.02.1995 on fees payable to the European Medicines Agency¹ and its implementing rules (hereafter ‘Fee Regulation Implementing Rules’).

This explanatory note does not include any fees or charges derived from the Regulation (EU) No 658/2014 of the European Parliament and of the Council of 15.05.2014 on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use². For information on these fees, please see explanatory note on pharmacovigilance fees payable to the European Medicines Agency.

Disclaimer:

This explanatory note is meant as a guidance note only. In case of discrepancies between the text and amounts of fees payable to the Agency quoted in the explanatory note and the provisions of the Council Regulation (EC) No 297/95, the latter document prevails.

Changes introduced in this version (1 April 2022)

- Increase in the level of fees (other than pharmacovigilance annual fees) to adjust for an inflation rate of +0.3% for 2020 and + 5.3% for 2021 and rounding off to the nearest EUR 10.
- Clarification on fees for cancellation of inspections in heading 1.1.7
- Introduction of scientific service fees for vaccine antigen master files and vaccine platform technology master files for veterinary medicines in headings 2.4.3 and 2.4.4
- New example on the determination of fee for companion diagnostics in Annex A1.1.4.3
- New example (Scenario 5 and 6) for new submission with additional strengths on a new pharmaceutical form in Annex A.1.1.3 for the determination of fees for extensions of marketing authorisation

¹ Official Journal L35, 15.02.1995, p. 1
² Official Journal L189, 27.06.2014, p. 112
Table of contents

1. Medicinal products for human use................................................................. 6
   1.1. Centralised procedure ............................................................................. 6
   1.2. Scientific advice ..................................................................................... 12
   1.3. Scientific services ................................................................................. 14
   1.4. Consultation on medical devices ............................................................. 15
   1.5. Certification of compliance with European Union legislation for plasma master files (PMF) and vaccine antigen master files (VAMF) ................................................................. 18

2. Veterinary medicinal products ...................................................................... 23
   2.1. Centralised procedure ............................................................................. 23
   2.2. Maximum residue limits (MRLs) .............................................................. 29
   2.3. Scientific advice ..................................................................................... 31
   2.4. Scientific services ................................................................................. 32

3. Administrative fees ........................................................................................ 35
   3.1. Negative validation ................................................................................. 35
   3.2. Certificate of a medicinal product ............................................................. 35
   3.3. Notification of parallel distribution .......................................................... 36
   3.4. Worksharing procedures for variations to marketing authorisations ........ 37

4. Fee determination and payment .................................................................. 39
   4.1. Legal requirements ................................................................................. 39
   4.2. Criteria for fee determination ................................................................. 41
   4.3. Established fee exemptions ................................................................. 41
   4.4. Request for ad hoc fee reduction .............................................................. 41

5. Fee exemptions .............................................................................................. 43
   5.1. Micro, small or medium-sized enterprise ............................................. 43
   5.2. Orphan medicinal products ................................................................. 44
   5.3. Multiple applications on usage patent grounds ...................................... 45
   5.4. Medicinal products for paediatric use .................................................... 48
   5.5. Advanced therapy medicinal products .................................................. 48
   5.6. Core dossier medicinal products to be used in a human pandemic situation ................................................................. 49
   5.7. Veterinary medicinal products for limited markets .............................. 50
   5.8. Deleted ................................................................................................. 51
   5.9. Veterinary vaccines against certain epizootic diseases ....................... 51
   5.10. Scientific advice for PRIME scheme ...................................................... 51
   5.11. Vaccines authorised under exceptional circumstances for preparedness against biological agents ......................................................................................... 51
   5.12. Scientific advice on clinical trial protocols pursuant to Article 16(2) of Regulation 2022/123 ................................................................................................. 52

Annex .................................................................................................................. 55
   A.1. Medicinal products for human use ......................................................... 55
   A.1.1.2. Examples of the determination of fees for applications for marketing authorisation ................................................................. 55
   A.1.1.3. Examples of the determination of fees for extensions of marketing authorisation ................................................................. 60
   A.1.1.4. Examples of the determination of fees for variations to a marketing authorisation introducing new presentations (i.e. EU sub-numbers) ................................................................. 64

Explanatory note on general fees payable to the European Medicines Agency
EMA/596331/2021

Page 3/85
A.1.1.6. Examples of the determination of fees for renewals of marketing authorisation .... 66
A.1.1.7.1. Examples of the determination of fees for GMP inspections ......................... 68
A.1.1.7.2. Examples of the determination of fees for GCP inspections ......................... 71
A.1.4.3 Examples of the determination of fees for applications for companion diagnostics devices ........................................................................................................................................ 74
A.2. Veterinary medicinal products ................................................................................. 76
A.2.1.2. Examples of the determination of fees for applications for marketing authorisation 76
A.2.1.4. Examples of the determination of fees for VRA level 1 of marketing authorisation .78
A.3. Administrative fees .................................................................................................. 82
A.3.2. Examples of the determination of fees for certificates of medicinal product ........ 82
Medicinal products for human use
1. Medicinal products for human use

Note: This section on fees for medicinal products for human use should be read in conjunction with the section on fee exemptions (Section 5) and the annex.

1.1. Centralised procedure

1.1.1. Definitions

*Pharmaceutical form:* According to the ‘Standard Terms’ published by the Council of Europe.

*Strength:* See definition used in the pre-submission guidance.

*Presentation:* Each unit/entity of a certain strength and form of a pharmaceutical product which will be individually authorised and eventually marketed (= each individual sub-number).

1.1.2. Application for a marketing authorisation

1.1.2.1. Application for which a full dossier needs to be presented

<table>
<thead>
<tr>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>313 200 EURO</strong></td>
<td>Basic fee For a single strength associated with one pharmaceutical form and one presentation.</td>
</tr>
<tr>
<td><strong>+ 31 500 EURO</strong></td>
<td>Additional fee For each additional strength or pharmaceutical form including one presentation, submitted at the same time as the initial application for authorisation.</td>
</tr>
<tr>
<td><strong>+ 7 800 EURO</strong></td>
<td>Additional fee For each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.</td>
</tr>
</tbody>
</table>

1.1.2.2. Application for which a full dossier need not be presented

<table>
<thead>
<tr>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>202 500 EURO</strong></td>
<td>Basic fee For an application for a marketing authorisation pursuant to Article 10(4) of Directive 2001/83/EC. This fee is for a single strength associated with one pharmaceutical form and one presentation.</td>
</tr>
<tr>
<td><strong>+ 12 100 EURO</strong></td>
<td>Additional fee For each additional strength or pharmaceutical form including one presentation submitted at the same time as the initial application for authorisation.</td>
</tr>
<tr>
<td><strong>+ 7 800EURO</strong></td>
<td>Additional fee For each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.</td>
</tr>
</tbody>
</table>
Basic fee

121 500 EURO
For applications for a marketing authorisation pursuant to Article 10(1), Article 10(3) and Article 10c of Directive 2001/83/EC. This fee is for a single strength associated with one pharmaceutical form and one presentation.

Additional fee

+ 12 100 EURO
For each additional strength or pharmaceutical form including one presentation submitted at the same time as the initial application for authorisation.

Additional fee

+ 7 800 EURO
For each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.

Note: Refer to section A.1.1.2. in the annex for examples of the determination of fees for applications for marketing authorisation.

1.1.3. Extension of a marketing authorisation

1.1.3.1. Extension of a marketing authorisation under Annex I to Commission Regulation (EC) No 1234/2008

Basic fee (Level I)

94 000 EURO
For each extension of a marketing authorisation within the meaning of Annex I to Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use. This fee is for a single strength/potency associated with one pharmaceutical form and one presentation.

Additional fee

+ 23 700 EURO
For each additional strength/potency of the same pharmaceutical form of the same extension including one presentation submitted at the time of the extension application.

Additional fee

+ 7 800 EURO
For each additional presentation of the same strength/potency of the same pharmaceutical form of the same extension submitted at the time of the extension application.

Basic fee (Level II)

70 600 EURO
For all quality extensions (i.e. requiring chemical, pharmaceutical and biological documentation) for which no clinical or non-clinical data are submitted or no cross-references to previously submitted clinical or non-clinical data are made by the MAH. This fee is for a single strength/potency associated with one pharmaceutical form and one presentation. (Note: Bioequivalence data qualify as clinical data. Biowaiver dossiers are not considered as clinical data.)

Additional fee

+23 700 EURO
For each additional strength/potency of the same pharmaceutical form of the same extension including one presentation submitted at the time of the extension application.
1.1.3.2. Extension of a marketing authorisation for use in the paediatric population under Article 29 of Regulation (EC) No 1901/2006

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee (Level III)</td>
<td>94 000 EURO</td>
<td>For each extension of a marketing authorisation made under Article 29 of Regulation (EC) No 1901/2006 on medicinal products for paediatric use. This fee is for a single strength/potency associated with one pharmaceutical form and one presentation.</td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ 23 700 EURO</td>
<td>For each additional strength/potency of the same pharmaceutical form of the same extension including one presentation submitted at the time of the extension application.</td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ 7 800 EURO</td>
<td>For each additional presentation of the same strength/potency of the same pharmaceutical form of the same extension submitted at the time of the initial extension application.</td>
</tr>
</tbody>
</table>

**Note:** Refer to section A.1.1.3. in the annex for examples of the determination of fees for extensions of marketing authorisation.

1.1.4. Variation to a marketing authorisation

When a change affecting different strengths, pharmaceutical forms and/or presentations is introduced through a variation (e.g. to add of a new manufacturing site for active substance, to update the safety data on the product information), the corresponding fee for the variation covers all authorised strengths, pharmaceutical forms and presentations of a given medicinal product (= per main authorisation number).

The introduction of a new pack size (i.e. new Marketing Authorisation sub-number) is considered as a distinct change to the Marketing Authorisation that should be submitted as a single variation for each strength and pharmaceutical form of a given medicinal product (i.e. one variation per new Marketing Authorisation sub-number). Section A.1.1.4. in the annex includes an example of determination of fee for additional pack sizes.

The following fees apply to variations that are notified or applied for individually in a notification or application.

1.1.4.1. Type-IA variation

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>3 500 EURO</td>
<td>For a minor variation to a marketing authorisation, as defined in Article 2(2) of Commission Regulation (EC) No 1234/2008.</td>
</tr>
</tbody>
</table>

The fee shall be charged regardless of the outcome (positive, negative, or partial or full withdrawal).
1.1.4.2. Type-IB variation

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>7 800 EURO</td>
</tr>
<tr>
<td>For a minor variation to a marketing authorisation, as defined in Article 2(5) of Commission Regulation (EC) No 1234/2008.</td>
<td></td>
</tr>
</tbody>
</table>

1.1.4.3. Type-II variation

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee (Level I)</td>
<td>94 000 EURO</td>
</tr>
<tr>
<td>For a major variation to a marketing authorisation, as defined in Article 2(3) of Commission Regulation (EC) No 1234/2008.</td>
<td></td>
</tr>
<tr>
<td>Basic fee (Level II)</td>
<td>70 600 EURO</td>
</tr>
<tr>
<td>For a quality variation (i.e. amendments to the chemical, pharmaceutical and biological documentation) for which no clinical or non-clinical data are submitted or no cross-references to previously submitted clinical or non-clinical data are made by the MAH. (Note: Bioequivalence data qualify as clinical data. Biowaiver dossiers are not considered as clinical data.)</td>
<td></td>
</tr>
<tr>
<td>Basic fee (Level III)</td>
<td>23 700 EURO</td>
</tr>
<tr>
<td>For each of the third and subsequent type II variations that are grouped in a single application made under the terms of Article 7(2) of Commission Regulation (EC) No 1234/2008.</td>
<td></td>
</tr>
<tr>
<td>For each of the third and subsequent type II variations to the centralised marketing authorisation or to one of the centralised marketing authorisations, where there is more than one centralised marketing authorisation, in the case of a worksharing application made under the terms of Article 20 of Commission Regulation (EC) No 1234/2008.</td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>94 000 EURO</td>
</tr>
<tr>
<td>For each new indication for use in the paediatric population applied for under Article 29 of Regulation (EC) No 1901/2006 on medicinal products for paediatric use.</td>
<td></td>
</tr>
</tbody>
</table>

1.1.5. Grouping and worksharing procedures for variations

1.1.5.1. Grouping of extensions and/or variations notified or submitted under the terms of Article 7(2) of Commission Regulation (EC) No 1234/2008

- The applicable fee specified in sections 1.1.3 and 1.1.4 shall be payable for each individual extension and/or variation to a marketing authorisation that is grouped in a single notification or a single application.
- The applicable level I and level II basic fees specified in sub-section 1.1.4.3 above are payable for the first and second type II variation respectively when both levels of fees are applicable to variations in the same grouping.
- Subsequent variations in a grouping shall be similarly charged the applicable fees as specified above.
• In the case of grouping of the same Type IA variations to the terms of several marketing authorisations owned by the same holder (as set out in Article 7(2)(a) of Commission Regulation (EC) No 1234/2008), the applicable fee shall be payable for each individual Type IA variation and for each marketing authorisation in the grouping.

• The same marketing authorisation holder also means several marketing authorisation holders that are linked through a parent company. The fee for the grouping shall be payable by the marketing authorisation holder applying for the grouping procedure.

• Where any extensions/variations included in a grouping are found not to be valid and the remainder are validated positively, the applicable fees as specified above shall be payable for each of the positively validated extensions/variations.

1.1.5.2. **Worksharing procedure under the terms of Article 20 of Commission Regulation (EC) No 1234/2008**

• The applicable fee specified in section 1.1.4 is payable for each individual variation to one of the centralised marketing authorisations owned by the same holder, where more than one centralised marketing authorisation is included in the worksharing application, or to the single centralised marketing authorisation included in the worksharing application, as applicable.

• The applicable level I and level II basic fees specified in 1.1.4.3 above are payable for the first and second type II variation respectively when both levels of fees are applicable to variations in the same worksharing procedure.

• The administrative fee shown in the table below is additionally payable for each individual variation to each of the other centralised marketing authorisation(s) owned by the same holder included in the same worksharing application, if applicable.

• No fee is payable to the Agency for any national marketing authorisations included in the same worksharing application.

• The same marketing authorisation holder also means several marketing authorisation holders that are linked through a parent company. The fee for the worksharing procedure shall be payable by the marketing authorisation holder applying for the procedure.

<table>
<thead>
<tr>
<th>Variation type</th>
<th>Worksharing fees for one centralised marketing authorisation</th>
<th>Worksharing administrative fees for second and subsequent marketing authorisations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Excluding applications on usage patent grounds</td>
<td>Applications on usage patent grounds³</td>
</tr>
<tr>
<td>Type II (Level I)</td>
<td>94 000 EURO</td>
<td>7 840 EURO</td>
</tr>
<tr>
<td>Type II (Level II)</td>
<td>70 600 EURO</td>
<td>7 840 EURO</td>
</tr>
<tr>
<td>Type II (Level III)</td>
<td>23 700 EURO</td>
<td>1 310 EURO</td>
</tr>
<tr>
<td>Type IB</td>
<td>7 800 EURO</td>
<td></td>
</tr>
<tr>
<td>Type IA</td>
<td>3 500 EURO</td>
<td></td>
</tr>
</tbody>
</table>

³ These fees are applicable for as long as the concerned marketing authorisation is affected by usage patent(s) pertaining to indication(s) and/or dosage form(s). Refer to section 4.3 for further details on fee exemptions.
Where any variations included in a worksharing procedure are found not to be valid and the remainder are validated positively, the applicable fees as specified above shall be payable for each of the positively validated variations.

### 1.1.6. Renewal of a marketing authorisation

<table>
<thead>
<tr>
<th>Basic fee</th>
<th>15 400 EURO</th>
</tr>
</thead>
</table>
| For each strength associated with a pharmaceutical form for which renewal is sought.

**Note:** Refer to section A.1.1.6. in the annex for examples of the determination of fees for renewals of marketing authorisation.

### 1.1.7. Inspection

<table>
<thead>
<tr>
<th>Basic fee (Level I)</th>
<th>23 700 EURO</th>
</tr>
</thead>
</table>
| For each inspection inside or outside the European Union; for inspections outside the European Union, travel expenses shall be charged extra on the basis of actual cost.

<table>
<thead>
<tr>
<th>Basic fee (Level II)</th>
<th>11 800 EURO</th>
</tr>
</thead>
</table>
| For each consecutive distinct plasma master file (PMF) inspection performed in conjunction with an inspection that attracts the level I fee, provided that such consecutive inspection concerns the same PMF application, the same inspection team and is conducted in the same PMF inspection tour.

<table>
<thead>
<tr>
<th>Basic fee (Level III)</th>
<th>11 800 EURO</th>
</tr>
</thead>
</table>
| For each inspection inside or outside the European Union cancelled due to the withdrawal of the application or intended application; or changes to the manufacturing arrangements made by the manufacturer or changes made by the applicant/prospective applicant/MAH that necessitate a cancellation of the inspection before the inspection is carried out.

**Note:** Refer to section A.1.1.7.1. in the annex for examples of the determination of fees for good manufacturing practice (GMP) inspections and to section A.1.1.7.2. in the annex for examples of the determination of fees for good clinical practise (GCP).

### 1.1.8. Transfer of a marketing authorisation

<table>
<thead>
<tr>
<th>Basic fee</th>
<th>7 800 EURO</th>
</tr>
</thead>
</table>
| For all authorised presentations of the medicinal product.

### 1.1.9. Maintenance of a marketing authorisation – Annual fee

<table>
<thead>
<tr>
<th>Basic fee (Level I)</th>
<th>112 200 EURO</th>
</tr>
</thead>
</table>
| For each marketing authorisation of a medicinal product. This fee covers all authorised presentations of the medicinal product.
Medicinal products for human use

Explanatory note on general fees payable to the European Medicines Agency
EMA/596331/2021

Page 12/85

**Basic fee (Level II)**

56 200 EURO

For each marketing authorisation of a biosimilar medicinal product (Article 10(4) of Directive 2001/83/EC). This fee covers all authorised presentations of the medicinal product.

**Basic fee (Level III)**

28 100 EURO

For each marketing authorisation of a generic, hybrid or informed consent medicinal product (Articles 10(1), 10(3) and 10c of Directive 2001/83/EC). This fee covers all authorised presentations of the medicinal product.

### 1.1.10. Referral

77 900 EURO

For procedures laid down in Article 30(1) and 31 of Directive 2001/83/EC that are initiated by the applicant of a marketing authorisation or the holder of an existing marketing authorisation.

**Note:** Where more than one applicant for marketing authorisation or holder of existing marketing authorisations are concerned by the procedures referred to in the first subparagraph, the applicants or holders may be grouped for the purpose of the payment of one single referral fee. If, however, the same procedure concerns more than 10 different applicants or holders, the fee will be charged by the application of the above mentioned referral fee.

The fee for procedures, which are initiated according to the second subparagraph of Article 31(1) of Directive 2001/83/EC, will be charged according to Article 6 of Regulation (EU) 658/2014 of 15 May 2014 (pharmacovigilance fee regulation).

### 1.2. Scientific advice

#### 1.2.1. Definitions

**Quality development:** Chemical, pharmaceutical and biological testing.

**Safety development:** Toxico logical and pharmacological tests.

**Clinical development:** Studies in human subjects, whether patients or non-patient volunteers, including clinical pharmacological trials designed to determine the efficacy and safety of the product; may also include guidance to demonstrate significant benefit over authorised medicines in the context of a designated orphan medicinal product.

**Qualification advice:** Advice on the acceptability of a specific use of the proposed method (e.g. use of a biomarker) in a research and development (R&D) context (non-clinical or clinical studies), based on the assessment of submitted data.

**Initial request:** First request for scientific advice or protocol assistance introduced in relation to the submission of an application for marketing authorisation or a variation, whatever the authorisation phase (pre- or post-authorisation).

**Follow-up to initial request:** Any subsequent request falling within the same therapeutic indication and initial area(s) as the initial request, (area meaning quality, preclinical and/or clinical development, including pharmacovigilance/risk management aspects).
### 1.2.2. Initial request for scientific advice

<table>
<thead>
<tr>
<th>Level I</th>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
</table>
| 46 900  | EURO | For *initial* requests on:  
  - quality development or  
  - safety development, or  
  - bioequivalence studies for generic medicinal products. |

<table>
<thead>
<tr>
<th>Level II</th>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
</table>
| 70 600  | EURO | For *initial* requests on:  
  - clinical development, or  
  - quality and safety development, or  
  - quality and bioequivalence studies for generic medicinal products. |

<table>
<thead>
<tr>
<th>Level III</th>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
</table>
| 94 000   | EURO | For *initial* requests for scientific advice on:  
  - Quality, and safety and clinical development, or  
  - quality and clinical development, or  
  - safety and clinical development, or  
  - qualification advice. |

### 1.2.3. Follow-up request for scientific advice

<table>
<thead>
<tr>
<th>Level I</th>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
</table>
| 23 700  | EURO | For *follow-up* to the initial request on:  
  - quality development, or  
  - safety development, or  
  - bioequivalence studies for generic medicinal products. |

<table>
<thead>
<tr>
<th>Level II</th>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
</table>
| 35 400  | EURO | For *follow-up* to the initial request on:  
  - clinical development, or  
  - quality and safety development, or  
  - quality and bioequivalence studies for generic medicinal products. |

<table>
<thead>
<tr>
<th>Level III</th>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
</table>
| 46 900   | EURO | For *follow-up* to the initial request on:  
  - quality and safety and clinical development, or  
  - quality and clinical development, or  
  - safety and clinical development, or  
  - qualification advice. |
1.3. **Scientific services**

A scientific service fee shall apply where an application is made for any scientific advice or opinion by a scientific Committee, which is not covered by Articles 3 to 7 or by Article 8(1).

1.3.1. **Scientific opinions pursuant to Article 58 of Regulation (EC) No 726/2004**

The basic and additional fees specified in section 1.1.2 apply by analogy for a scientific opinion for the evaluation of medicinal products for human use intended exclusively for markets outside the European Union. Likewise, the inspection fees in section 1.1.7 apply by analogy to any inspection undertaken for the purpose of assessment prior to an opinion.

Fees for post-opinion services and annual fees are charged according to the corresponding fees for centrally authorised products. Therefore, the fees specified in sections 1.1.3, 1.1.4, 1.1.5, 1.1.7 and 1.1.9 apply by analogy.

The fee incentives for micro, small and medium-sized enterprises apply to scientific services described in section 5.1.2. However, fee deferrals and conditional fee exemptions do not apply to services in relation to scientific opinions pursuant to Article 58 of Regulation (EC) No 726/2004.

1.3.2. **Compassionate use**

- **Basic fee**
  - **156 700 EURO**
  - For any opinion on medicinal products for compassionate use.
  - This fee will be deducted from the fee charged for a subsequent application for marketing authorisation by the same applicant.

1.3.3. **Herbal medicinal products**

- **Basic fee (Level I)**
  - **23 700 EURO**
  - For requests for scientific support and advice by the Committee on Herbal Medicinal Products (HMPC) on multiple areas related to traditional herbal medicinal products.

- **Basic fee (Level II)**
  - **15 400 EURO**
  - For requests for scientific support and advice by the HMPC on single areas related to traditional herbal medicinal products, for example:
    - quality, or
    - safety, or
    - long-standing use.

1.3.4. **Certification of quality and non-clinical data relating to advanced therapy medicinal products developed by micro, small and medium-sized enterprises**

- **Basic fee**
  - **70 600 EURO**
  - Evaluation of an application relating to quality and non-clinical data.
1.3.5. Rolling Review

**Basic fee**

156 700 EURO

For any application for a ‘Rolling Review’ Assessment for potential marketing authorisations in a human pandemic situation.

This fee will be deducted from the fee charged for a subsequent application for marketing authorisation by the same applicant. In case of multiple Rolling Review cycles this fee will only be charged once.

1.4. Consultation on medical devices

For the establishment of fee fees applying to consultation on medical device, the following definitions are applied:

- **Initial request**: first request for consultation on a medical device.
- **Follow-up to initial request**: any subsequent request for a consultation on a device that previously underwent an initial consultation with the EMA.

The fee incentives for micro, small and medium-sized enterprises apply to scientific services described in section 5.1.2.

The fees payable for consultations on medical devices shall be charged to the medical device manufacturer that, according to the application form submitted to the Agency, requested the assessment of conformity of the medical device by the notified body on the basis of which the consultation is applied for.

1.4.1. Ancillary substances including blood derivatives incorporated in medical devices

The determination of the fee shall be guided by the following principles:

- Where a device incorporates two or more ancillary substances/derivatives, the fee relates to one of the substances/derivatives only – the one that commands the highest fee.
- One application may include a range of strengths or concentrations of the ancillary substance/derivative and/or a range of similar devices (e.g. a range of catheters made of the same material) incorporating the same substance/derivative from the same manufacturer.

1.4.1.1. Initial request

**Basic fee**

94 000 EURO

For consultation on an ancillary medicinal substance or blood derivative new to the centralised procedure. This fee applies where the substance/derivative from the specified manufacturer has not been evaluated by the Agency in connection with a previous marketing authorisation and/or through a previous successful
notified body consultation.

### 70 600 EURO
For consultation on a known ancillary blood derivative from a known source. This fee applies where the blood derivative from the specified manufacturer has been evaluated by the Agency in connection with a previous marketing authorisation and/or through a previous successful notified body consultation.

### 46 900 EURO
For consultation on a known ancillary medicinal substance from a known source. This fee applies where the substance from the specified manufacturer has been evaluated by the Agency in connection with a previous marketing authorisation and/or through a previous successful notified body consultation.

#### 1.4.1.2. Follow-up to the initial request

### 46 900 EURO
For consultation on an amendment to the documentation on an ancillary medicinal substance or blood derivative already evaluated by the Agency (The amendments should be classified by analogy to Annex I of Commission Regulation (EC) No 1234/2008).

### 46 900 EURO
For consultation on a major amendment to the documentation on an ancillary medicinal substance or blood derivative already evaluated by the Agency (The amendment should be equivalent to a Type II variation as classified by analogy to Commission Regulation (EC) No 1234/2008).

### 46 900 EURO
For consultation on two or more amendments to the documentation on an ancillary medicinal substance or blood derivative already evaluated by the Agency that are grouped in a single application by analogy to the terms of Articles 7(2)(b) or 7(2)(c) of Commission Regulation (EC) No 1234/2008 where at least one of the amendments is classified by analogy to Annex I of Commission Regulation (EC) No 1234/2008 or as a major amendment.

### 7 800 EURO
For consultation on a minor amendment to the documentation on an ancillary medicinal substance or blood derivative already evaluated by the Agency. (The amendment should be equivalent to a Type IB variation as classified by analogy to Commission Regulation (EC) No 1234/2008).

### 3 500 EURO
For consultation on a minor amendment to the documentation on an ancillary medicinal substance or blood derivative already evaluated by the Agency. (The amendment should be equivalent to a Type IA variation as classified by analogy to Commission Regulation (EC) No 1234/2008).
1.4.2. Medical devices composed of substances or combinations of substances that are systemically absorbed to achieve their intended purpose

1.4.2.1. Initial request

The determination of the fee shall be guided by the following principles:

- Where a device is composed of two or more substances the consultation commands one fee only.
- One application may include a range of presentations of the substance(s) from the same manufacturer.

<table>
<thead>
<tr>
<th>70 600 EURO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
</tr>
<tr>
<td>For consultation on the compliance of medical devices composed of substance(s) or combination of substances that are systemically absorbed to achieve their intended purpose with the relevant requirements of Annex I to Directive 2001/83/EC.</td>
</tr>
</tbody>
</table>

1.4.3. Companion diagnostics

1.4.3.1. Initial request

The determination of the fee shall be guided by the following principles:

- The consultation will be charged for suitability of the device to medicinal product(s) containing the same active substance(s) or the same combination of active substances\(^4\)
- Applications for consultation submitted simultaneously for suitability of the device in relation to more than one active substance(s) or combination of substances will incur an added charge per additional active substance or combination of substances up to a maximum fee.

<table>
<thead>
<tr>
<th>46 900 EURO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
</tr>
<tr>
<td>For consultation on the suitability of a companion diagnostic in relation to a concerned medicinal product. This fee applies in case a consultation is requested by a notified body to support a new conformity assessment. The consultation will be charged at fee of EUR 44 400 for suitability of the device to medicinal product(s) containing the same active substance(s) or the same combination of active substances.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>+ 7 800 EURO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional fee</td>
</tr>
<tr>
<td>For applications submitted simultaneously for suitability of the device in relation to each additional active substance or combination of substances up to a maximum total fee of EUR 89 000.</td>
</tr>
</tbody>
</table>

\(^4\) In the context of the consultation for companion diagnostics, the different salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance shall be considered to be the same active substance, unless they differ significantly in properties with regard to safety and/or efficacy.
1.4.3.2. Follow-up to the initial request

<table>
<thead>
<tr>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 700 EURO</td>
<td>For consultation on an amendment to the documentation of a companion diagnostic already evaluated by the Agency in connection with a previous successful notified body consultation. In this case a further consultation is requested by a notified body after a first consultation, in response to changes to a companion diagnostic that affect the performance and/or the intended use and/or the suitability of the device in relation to the medicinal product(s) concerned, which results in a supplement to the EU technical documentation assessment certificate or EU type-examination certificate.</td>
</tr>
</tbody>
</table>

1.5. Certification of compliance with European Union legislation for plasma master files (PMF) and vaccine antigen master files (VAMF)

1.5.1. Application for PMF certification (initial certification)

1.5.1.1. Not submitted simultaneously with a new application under the centralised procedure

<table>
<thead>
<tr>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77 900 EURO</td>
<td>For the review of the PMF and its initial certification where the data contained in the PMF have not been previously evaluated within the centralised procedure.</td>
</tr>
<tr>
<td>70 600 EURO</td>
<td>For the review of the PMF and its initial certification where the PMF applicant has included change(s) to the data previously evaluated within the centralised procedure and which are now part of the PMF application.</td>
</tr>
<tr>
<td>23 700 EURO</td>
<td>For the review of the PMF and its initial certification where the data contained in the PMF have been previously evaluated under the centralised procedure and no changes have been included.</td>
</tr>
</tbody>
</table>

1.5.1.2. Submitted simultaneously with a new application under the centralised procedure

<table>
<thead>
<tr>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 800 EURO</td>
<td>For the review of the PMF and its certification when it is submitted in parallel and within the submission of a new application within the centralised procedure. The PMF documentation will be evaluated by the Agency simultaneously with a centralised marketing authorisation application.</td>
</tr>
</tbody>
</table>

1.5.2. Variation to a certified PMF

<table>
<thead>
<tr>
<th>Fee</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>70 600 EURO</td>
<td>For the review and certification of a major variation to the PMF (in accordance with Commission Regulation (EC) No 1234/2008).</td>
</tr>
<tr>
<td>70 600 EURO</td>
<td>For the review and certification of two or more variations that are grouped in a single application made under the terms of Articles 7(2)(b) or 7(2)(c) of</td>
</tr>
</tbody>
</table>
### 1.5.3. Annual re-certification of PMF

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the review and annual re-certification of the PMF under this scheme</td>
<td>70 600 EURO</td>
</tr>
<tr>
<td>where one or more variations are included in the submitted documentation</td>
<td></td>
</tr>
<tr>
<td>and at least one of the variations is a major variation.</td>
<td></td>
</tr>
<tr>
<td>For the review and annual re-certification of the PMF under this scheme</td>
<td>15 400 EURO</td>
</tr>
<tr>
<td>where no major variations are included in the submitted documentation.</td>
<td></td>
</tr>
<tr>
<td>This fee is increased by the applicable fee for each minor variation of</td>
<td></td>
</tr>
<tr>
<td>type IA or type IB included in the submitted documentation, up to a</td>
<td></td>
</tr>
<tr>
<td>maximum total fee of 66 800 EURO.</td>
<td></td>
</tr>
</tbody>
</table>

### 1.5.4. Application for a VAMF certification (initial certification)

#### 1.5.4.1. Not submitted simultaneously with a new application under the centralised procedure

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the review of the VAMF and its certification where the data contained</td>
<td>77 900 EURO</td>
</tr>
<tr>
<td>in the vaccine antigen master file have not been previously evaluated</td>
<td></td>
</tr>
<tr>
<td>within the centralised procedure. In the case of a group of antigens aimed</td>
<td></td>
</tr>
<tr>
<td>at preventing a single infectious disease, e.g. inactivated polio serotypes</td>
<td></td>
</tr>
<tr>
<td>1, 2 and 3, the VAMF application for one antigen will be charged at the</td>
<td></td>
</tr>
<tr>
<td>above fee.</td>
<td></td>
</tr>
<tr>
<td>For each VAMF application submitted simultaneously for antigens from the</td>
<td>+ 7 800 EURO</td>
</tr>
<tr>
<td>same group, up to a maximum total fee of 89 000 EURO.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the review of the VAMF and its certification where the initial data</td>
<td>70 600 EURO</td>
</tr>
<tr>
<td>have been previously evaluated within the centralised procedure but where</td>
<td></td>
</tr>
<tr>
<td>the VAMF applicant has included changes or harmonisation as part of the</td>
<td></td>
</tr>
<tr>
<td>VAMF certification scheme.</td>
<td></td>
</tr>
<tr>
<td>In the case of a group of antigens aimed at preventing a single infectious</td>
<td></td>
</tr>
<tr>
<td>disease e.g. inactivated polio serotypes 1, 2 and 3, the VAMF application</td>
<td></td>
</tr>
<tr>
<td>for one antigen will be charged at the above fee.</td>
<td></td>
</tr>
</tbody>
</table>
### 1.5.4.2. Submitted simultaneously with a new application under the centralised procedure

<table>
<thead>
<tr>
<th>Fee Description</th>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>7 800 EURO</td>
<td>For the review of the VAMF and its certification when it is submitted in parallel and within the submission of a new application containing the named antigen within the centralised procedure. In the case of a group of antigens aimed at preventing a single infectious disease e.g. inactivated Polio serotypes 1, 2 and 3, the VAMF application for one antigen will be charged at the above fee.</td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ 7 800 EURO</td>
<td>For each VAMF application submitted simultaneously for antigens from the same group, up to a maximum total fee of 89 000 EURO.</td>
</tr>
</tbody>
</table>

### 1.5.5. Variation to a certified VAMF

<table>
<thead>
<tr>
<th>Fee Description</th>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>70 600 EURO</td>
<td>For the review and certification of a major variation to the VAMF (in accordance with Commission Regulation (EC) No 1234/2008). In the case of a group of antigens aimed at preventing a single infectious disease e.g. inactivated polio serotypes 1, 2 and 3, the VAMF application for one antigen will be charged at the above fee.</td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ 7 800 EURO</td>
<td>For each VAMF application submitted simultaneously for antigens from the same group, up to a maximum total fee of 89 000 EURO.</td>
</tr>
</tbody>
</table>

---

*Explanatory note on general fees payable to the European Medicines Agency*  
EMA/596331/2021  
Page 20/85
In the case of a group of antigens aimed at preventing a single infectious disease e.g. inactivated polio serotypes 1, 2 and 3, the grouped variations application for one antigen will be charged at the above fee.

**+ 7 800 EURO**

For each VAMF grouping application submitted simultaneously for antigens from the same group, up to a maximum total fee of 89 000 EURO.

---

Basic fee  

**7 800 EURO**

For the review and certification of a minor variation of type IB to the VAMF (in accordance with Commission Regulation (EC) No 1234/2008).

In the case of a group of antigens aimed at preventing a single infectious disease e.g. inactivated polio serotypes 1, 2 and 3, the VAMF application for one antigen will be charged at the above fee.

**+ 7 800 EURO**

For each VAMF applications submitted simultaneously for antigens from the same group, up to a maximum total fee of 44 400 EURO.

---

Basic fee  

**3 500 EURO**

For the review and certification of a minor variation of type IA to the VAMF (in accordance with Commission Regulation (EC) No 1234/2008).

In the case of a group of antigens aimed at preventing a single infectious disease e.g. inactivated polio serotypes 1, 2 and 3, the VAMF application for one antigen will be charged at the above fee.

**+ 3 500 EURO**

For each VAMF application submitted simultaneously for antigens from the same group, up to a maximum total fee of 22 400 EURO.
Veterinary medicinal products
2. Veterinary medicinal products

Note: This section on fees for veterinary medicinal products should be read in conjunction with the section on fee exemptions (Section 5) and the annex.

2.1. Centralised procedure

2.1.1. Definitions

*Pharmaceutical form:* According to the ‘Standard Terms’ published by the Council of Europe.

*Strength:* See [definition](#) used in the pre-submission guidance.

*Presentation:* Each unit/entity of a certain strength and form of a pharmaceutical product which will be individually authorised and eventually marketed (= each individual sub-number).

2.1.2. Application for a marketing authorisation

2.1.2.1. Full fee

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>156 700 EURO</td>
</tr>
<tr>
<td>For a single strength associated with one pharmaceutical form and one presentation.</td>
<td></td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ 15 400 EURO</td>
</tr>
<tr>
<td>For each additional strength or pharmaceutical form including one presentation, submitted at the same time as the initial application for authorisation.</td>
<td></td>
</tr>
<tr>
<td>+ 7 800 EURO</td>
<td></td>
</tr>
<tr>
<td>For each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.</td>
<td></td>
</tr>
</tbody>
</table>

Number of target species applied for does not impact on the fee.

2.1.2.2. Full fee – Immunologicals

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>77 900 EURO</td>
</tr>
<tr>
<td>For a single strength associated with one pharmaceutical form and one presentation.</td>
<td></td>
</tr>
<tr>
<td>Additional fee (I)</td>
<td>+ 7 800 EURO</td>
</tr>
<tr>
<td>For each additional strength or pharmaceutical form including one presentation submitted at the same time as the initial application for authorisation.</td>
<td></td>
</tr>
<tr>
<td>Additional fee (I)</td>
<td>+ 7 800 EURO</td>
</tr>
<tr>
<td>For each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.</td>
<td></td>
</tr>
</tbody>
</table>
### 2.1.2.3. **Reduced fee**

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic fee</strong></td>
<td>For applications for marketing authorisation pursuant to Article 18, 19 (except for the veterinary medicinal products covered in the table below) 21 and 23 of Regulation (EU) 2019/6. This fee is for a single strength associated with one pharmaceutical form and one presentation.</td>
<td><strong>77 900 EURO</strong></td>
</tr>
<tr>
<td><strong>Additional fee</strong></td>
<td>For each additional strength or pharmaceutical form including one presentation submitted at the same time as the initial application for authorisation.</td>
<td><strong>+ 15 400 EURO</strong></td>
</tr>
<tr>
<td><strong>Additional fee</strong></td>
<td>For each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.</td>
<td><strong>+ 7 800 EURO</strong></td>
</tr>
</tbody>
</table>

The number of target species applied for does not impact on the fee.
### 2.1.2.4. Reduced fee – Immunologicals

<table>
<thead>
<tr>
<th>Fee Level</th>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>For a single strength associated with one pharmaceutical form and one presentation.</td>
<td>39,200 EUR</td>
</tr>
<tr>
<td>Additional fee</td>
<td>For each additional strength or pharmaceutical form including one presentation submitted at the same time as the initial application for authorisation.</td>
<td>+ 7,800 EUR</td>
</tr>
<tr>
<td>Additional fee</td>
<td>For each additional presentation of the same strength and pharmaceutical form, submitted at the same time as the initial application for authorisation.</td>
<td>+ 7,800 EUR</td>
</tr>
</tbody>
</table>

The number of target species applied for does not impact on the fee.

**Note:** Refer to section A.2.1.2. in the annex for examples of the determination of fees for applications for marketing authorisation.

### 2.1.3. Deleted

### 2.1.4. Variation to a marketing authorisation requiring assessment (VRA)

When a change affecting different strengths, pharmaceutical forms and/or presentations is introduced through a variation (e.g. to add of a new manufacturing site for active substance, to update the safety data on the product information), the corresponding fee for the variation covers all authorised strengths, pharmaceutical forms and presentations of a given medicinal product (= per main authorisation number) except for Level 1 VRA for which additional fees are foreseen for additional presentation or strength/potency included in the same variation.

The following fees apply to variations requiring assessment that are notified or applied for individually in an application.

#### 2.1.4.1. Variation requiring assessment introducing changes of active substance(s), strength, pharmaceutical form, route of administration or food-producing target species (Level 1 VRA)

<table>
<thead>
<tr>
<th>Fee Level</th>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>For a variation requiring assessment that introduces changes of route of administration or food-producing target species</td>
<td>39,200 EUR</td>
</tr>
<tr>
<td>Basic fee (Level II)</td>
<td>For a variation requiring assessment that introduces changes of active substance(s), strength or pharmaceutical form, i.e. for which no clinical or non-clinical data are submitted or no cross-references to previously submitted clinical or non-clinical data are made by the marketing authorisation holder</td>
<td>35,400 EUR</td>
</tr>
<tr>
<td>Basic fee</td>
<td>For immunological veterinary medicinal products for a variation requiring assessment that introduces changes of active substance(s), strength or...</td>
<td>9,700 EUR</td>
</tr>
</tbody>
</table>

---

Published Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation (EU) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations.
### 2.1.4.2. Variation requiring assessment introducing safety, efficacy or pharmacovigilance changes (Level 2 VRA)

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>For variations requiring assessment that introduce changes to safety, efficacy or pharmacovigilance, which follow an extended (90 days) or a standard (60 days) timetable</td>
<td><strong>46 900 EURO</strong></td>
</tr>
<tr>
<td>For immunological veterinary medicinal products for variations requiring assessment that introduce changes to safety, efficacy or pharmacovigilance, which follow an extended (90 days) or a standard (60 days) timetable</td>
<td><strong>7 800 EURO</strong></td>
</tr>
<tr>
<td>For each of the third and subsequent variation introducing changes specified for the Level 2 VRA basic fee level I above that is grouped in a single application made under the terms of Article 64 of Regulation (EU) 2019/6.</td>
<td><strong>11 800 EURO</strong></td>
</tr>
<tr>
<td>For each of the third and subsequent variation introducing changes specified for the Level 2 VRA basic fee level I above in the case of a worksharing application under Article 65 of Regulation (EU) 2019/6.</td>
<td></td>
</tr>
</tbody>
</table>

### 2.1.4.3. Variation requiring assessment introducing quality changes (Level 3 VRA)

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>For variations requiring assessment introducing quality changes only, which follow a standard (60 days) timetable, i.e. all amendments to the chemical, pharmaceutical and biological documentation, for which no clinical or non-clinical data are submitted or no cross-references to previously submitted clinical or non-clinical data are made by the marketing authorisation holder</td>
<td><strong>35 400 EURO</strong></td>
</tr>
<tr>
<td>For immunological veterinary medicinal products for variations requiring assessment introducing quality changes only, which follow a standard (60 days) timetable, i.e. all amendments to the chemical, pharmaceutical and biological documentation, for which no clinical or non-clinical data are submitted or no cross-references to previously submitted clinical or non-clinical data are made by the marketing authorisation holder</td>
<td><strong>7 800 EURO</strong></td>
</tr>
</tbody>
</table>
2.1.4.4. Variation requiring assessment (VRA) reduced timetable (Level 4 VRA)

Basic fee (Level I)

7 800 EURO

For all variations requiring assessment which follow a reduced (30 days) timetable.

2.1.5. Grouping and worksharing procedures for variations

2.1.5.1. Grouping of variations requiring assessment submitted under the terms of Article 64 of Regulation (EU) 2019/6

- The applicable fees as specified in sub-section 2.1.4 shall be payable for each individual variation to a marketing authorisation that is grouped in a single application made under the terms of Article 64 of Regulation (EU) 2019/6.
- The applicable level I and level II basic fees specified in sub-section 2.1.4.2 and 2.1.4.3 above are payable for the first and second VRA respectively when both levels of fees are applicable to VRA in the same grouping.
- Subsequent variations in a grouping shall be similarly charged the applicable fees as specified above.
- The same marketing authorisation holder also means several marketing authorisation holders that are linked through a parent company. The fee for the grouping shall be payable by the marketing authorisation holder applying for the grouping procedure.
- Where any variation requiring assessment included in a grouping are found not to be valid and the remainder are validated positively, the applicable fees as specified above shall be payable for each of the positively validated variations requiring assessment.

2.1.5.2. Worksharing procedure under the terms of Article 65 of Regulation (EU) 2019/6

- The applicable fee specified in section 2.1.4 is payable for each individual variation to one of the centralised marketing authorisations owned by the same holder, where more than one centralised marketing authorisation is included in the worksharing application, or to the single centralised marketing authorisation included in the worksharing application, as applicable.
- The applicable level I and level II basic fees specified in 2.1.4.2 and 2.1.4.3 above are payable for the first and second VRA respectively, when both levels of fees are applicable to variations in the same worksharing procedure.
- The administrative fee shown in the table below is additionally payable for each individual VRA to each of the other centralised marketing authorisation(s) owned by the same holder included in the same worksharing application, if applicable.
• No fee is payable to the Agency for any national marketing authorisations included in the same worksharing application.

• The same marketing authorisation holder also means several marketing authorisation holders that are linked through a parent company. The fee for the worksharing procedure shall be payable by the marketing authorisation holder applying for the procedure.

<table>
<thead>
<tr>
<th>Variation type</th>
<th>Worksharing fees for one centralised marketing authorisation</th>
<th>Worksharing administrative fees for second and subsequent marketing authorisations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Excluding applications on usage patent grounds</td>
</tr>
<tr>
<td>VRA Level 2 basic fee level I</td>
<td>46 900 EURO</td>
<td>3 890 EURO</td>
</tr>
<tr>
<td>VRA Level 3 basic fee level I</td>
<td>35 400 EURO</td>
<td></td>
</tr>
<tr>
<td>VRA Level 2 and 3 basic fee level III</td>
<td>11 800 EURO</td>
<td></td>
</tr>
<tr>
<td>VRA Level 2 and 3 basic fee level II</td>
<td>7 800 EURO</td>
<td></td>
</tr>
<tr>
<td>VRA Level 4</td>
<td>7 800 EURO</td>
<td></td>
</tr>
</tbody>
</table>

Where any variations included in a worksharing procedure are found not to be valid and the remainder are validated positively, the applicable fees as specified above shall be payable for each of the positively validated variations.

2.1.6. Deleted

2.1.7. Inspection

23 700 EURO

Basic fee (Level I)

For each inspection inside or outside the European Union; for inspections outside the European Union, travel expenses shall be charged extra on the basis of actual cost.

11 800 EURO

Basic fee (Level II)

For each inspection inside or outside the European Union cancelled due to the withdrawal of the application; or changes to the manufacturing arrangements made by the manufacturer or changes made by the applicant/MAH that necessitate a cancellation of the inspection before the inspection is carried out.

Note: Refer to section A.1.1.7.1. in the annex for examples of the determination of fees for good manufacturing practice (GMP) inspections and to section A.1.1.7.2. in the annex for examples of the determination of fees for good clinical practise (GCP).

⁶ These fees are applicable for as long as the concerned marketing authorisation is affected by usage patent(s) pertaining to indication(s) and/or dosage form(s). Refer to section 4.3 for further details on fee exemptions.
2.1.8. Transfer of a marketing authorisation

7 800 EURO
For all authorised presentations of the medicinal product.

2.1.9. Maintenance of a marketing authorisation – Annual fee

37 600 EURO
Basic fee (Level I)
For each marketing authorisation of a veterinary medicinal product. This fee covers all authorised presentations of the medicinal product.

18 700 EURO
Basic fee (Level II)
For each marketing authorisation of a similar biological veterinary medicinal products authorised pursuant to Article 19 of Regulation (EU) 2019/6. This fee covers all authorised presentations of the medicinal product.

9 200 EURO
Basic fee (Level III)
For each marketing authorisation of a veterinary medicinal product authorised pursuant to Articles 18, 19 (except for the medicinal products covered in basic fee level II above), 21 and 23 of Regulation (EU) 2019/6. This fee covers all authorised presentations of the medicinal product.

2.1.10. Referral

46 900 EURO
For the procedures laid down in Article 82 of Regulation (EU) 2019/6 initiated by the applicant of a marketing authorisation or the marketing authorisation holder.

Note: Where more than one applicant of marketing authorisations or holder of existing marketing authorisations are concerned by the procedures referred to in the first subparagraph, the applicants or holders may be grouped for the purpose of the payment of one single referral fee. If, however, the same procedure concerns more than 10 different applicants or holders, the fee will be charged by the application of the above-mentioned referral fee.

2.2. Maximum residue limits (MRLs)

77 900 EURO
Basic fee
For an application to set an initial MRL for a given substance intended to be used in veterinary medicinal products or in biocidal products used in animal husbandry.

23 700 EURO
For each application to modify or extend an existing MRL, as included in Table 1 of the Annex to Regulation (EEC) No 470/2009.

MRL fees shall be deducted from the fee payable for an application for marketing authorisation or an application to add a food-producing target species to a marketing authorisation for the medicinal product containing the substance for which an MRL has been set where such applications are submitted.
by the same applicant. However, this deduction may in total be no more than one half of the fee to which it applies.
2.3. Scientific advice

2.3.1. Definitions

The following definitions shall apply for the determination of fees for scientific advice requests.

**Quality development**: Chemical, pharmaceutical and biological testing.

**Safety development**: Toxicological and pharmacological tests.

**Clinical development**: Studies in animal patients, including clinical pharmacological trials designed to determine the efficacy and safety of the product.

**Initial request**: First request for scientific advice or protocol assistance introduced in relation to the submission of an application for marketing authorisation or a variation, whatever the authorisation phase (pre- or post-authorisation).

**Follow-up to initial request**: Any subsequent request falling within the same therapeutic indication and initial area(s) as the initial request, (area meaning quality, preclinical and/or clinical development including pharmacovigilance/risk management aspects).

2.3.2. Initial request for scientific advice

<table>
<thead>
<tr>
<th>Fee Level</th>
<th>Fee Amount</th>
<th>Description</th>
</tr>
</thead>
</table>
| Basic fee (Level I) | 15 400 EURO | For initial requests on:  
  - quality development, or  
  - safety development, or  
  - bioequivalence studies for generic medicinal products, or  
  - new MRL, or  
  - preliminary risk profile |
| Basic fee (Level II) | 23 700 EURO | For initial requests on:  
  - clinical development, or  
  - quality and safety development, or  
  - quality and bioequivalence studies for generic medicinal products. |
| Basic fee (Level III) | 46 900 EURO | This fee corresponds to an initial request for scientific advice (SA) on:  
  - quality and safety and clinical development, or  
  - quality and clinical development, or  
  - safety and clinical development. |
### 2.3.3. Follow-up request for scientific advice

<table>
<thead>
<tr>
<th>Level</th>
<th>Basic Fee</th>
<th>Description</th>
</tr>
</thead>
</table>
| I     | 11 800 EURO | For follow-up to the initial request on:  
- quality development, or  
- safety development  
- bioequivalence studies for generic medicinal products, or  
- new MRL, or  
- preliminary risk profile |
| II    | 15 400 EURO | For follow-up to the initial request on:  
- clinical development, or  
- quality and safety development, or  
- quality and bioequivalence studies for generic medicinal products. |
| III   | 23 700 EURO | For follow-up to the initial request on:  
- quality and safety and clinical development, or  
- quality and clinical development, or  
- safety and clinical development. |

### 2.4. Scientific services

A scientific service fee shall apply where an application is made for any scientific advice or opinion by a scientific committee, which is not covered by Articles 3 to 7 or by Article 8(1) of Council Regulation (EC) No 297/95.

#### 2.4.1. Assessment on requirement for full MRL evaluation

<table>
<thead>
<tr>
<th>Basic Fee</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 700 EURO</td>
<td>Assessment on whether a full MRL evaluation is required or not for a chemical-unlike biological substance.</td>
</tr>
</tbody>
</table>

#### 2.4.2. Classification for limited market and eligibility for Article 23 of Regulation (EU) 2019/6

<table>
<thead>
<tr>
<th>Basic Fee</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 800 EURO</td>
<td>For a request for classification of a veterinary medicinal product as intended for a limited market according to Article 4(29) and as eligible for authorisation according to Article 23 of Regulation (EU) 2019/6.</td>
</tr>
</tbody>
</table>
### 2.4.3. Certification of compliance with European Union legislation for vaccine antigen master files (VAMF)

<table>
<thead>
<tr>
<th>Fee Code</th>
<th>Fee Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic fee</strong></td>
<td>7 800 EURO</td>
<td>For the review of the VAMF and its certification when it is submitted in parallel and within the submission of a new application containing the named antigen within the centralised procedure.</td>
</tr>
<tr>
<td><strong>Additional fee</strong></td>
<td>+ 7 800 EURO</td>
<td>For each VAMF application submitted simultaneously in the context of the same new marketing authorisation application (e.g. multivalent vaccines) up to a maximum of EUR 23 400.</td>
</tr>
<tr>
<td><strong>Basic fee</strong></td>
<td>15 400 EURO</td>
<td>For the review of the VAMF and its certification where the initial data have been previously evaluated within the centralised, decentralised or mutual recognition procedure.</td>
</tr>
<tr>
<td><strong>Basic fee</strong></td>
<td>7 800 EURO</td>
<td>For review and certification of a variation requiring assessment to the VAMF in accordance with Commission Regulation (EU) 2019/6 and section 2.1.5 of this explanatory note.</td>
</tr>
</tbody>
</table>

### 2.4.4. Certification of compliance with European Union legislation for vaccine platform technology master files (vPTMF)

<table>
<thead>
<tr>
<th>Fee Code</th>
<th>Fee Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic fee</strong></td>
<td>7 800 EURO</td>
<td>For the review of the vPTMF and its certification when it is submitted in parallel and within the submission of a new application containing the named platform within the centralised procedure.</td>
</tr>
<tr>
<td><strong>Basic fee</strong></td>
<td>15 400 EURO</td>
<td>For the review of the vPTMF and its certification for a platform in vaccine(s) already authorised via the centralised, decentralised or mutual recognition procedure.</td>
</tr>
<tr>
<td><strong>Basic fee</strong></td>
<td>7 800 EURO</td>
<td>For review and certification of a variation requiring assessment to the vPTMF in accordance with Commission Regulation (EU) 2019/6 and section 2.1.5 of this explanatory note.</td>
</tr>
</tbody>
</table>
Administrative fees
3. Administrative fees

3.1. Negative validation

- **3 400 EURO**
  - Basic fee
  - For an application that has been found not to be valid, an administrative fee for the validation of the application shall be charged.
  - This fee is for all negative validations except for grouping or worksharing applications.

- **3 400 EURO**
  - Basic fee
  - For a grouping or worksharing application where all extensions/variations in the application have been found not to be valid.
  - If individual extensions/variations in an application are found not to be valid but the remainder are validated positively, no administrative fee shall be charged for the invalid extensions/variations.

3.2. Certificate of a medicinal product

3.2.1. Definitions

A *set of certificates*: a maximum of six identical original certificates for a medicinal product with a distinct marketing authorisation number, addressed to the same importing country, issued in the same official language of the European Union and having identical annexes.

*Standard procedure*: procedure for issuing certificates of medicinal product within 10 working days.

*Urgent procedure*: procedure for issuing certificates of medicinal product within 2 working days.

3.2.2. Standard procedure

- **320 EURO**
  - Basic fee (Level I)
  - For each request for certificates, including one set of certificates.

- **+ 160 EURO**
  - Additional fee
  - For each additional set of certificates included in the same request.

3.2.3. Urgent procedure

- **960 EURO**
  - Basic fee (Level II)
  - For each request for certificates, including one set of certificates.
Additional fee + 480 EURO
For each additional set of certificates included in the same request.

3.2.4. Withdrawal of request for certificates

Basic fee 320 EURO
When a request for certificates is withdrawn by the requester following confirmation by the Agency of the start of the procedure.

Note: Refer to section A.3.2. in the annex for examples of the determination of fees for certificates of medicinal product.

3.3. Notification of parallel distribution

Initial notification of parallel distribution 3 400 EURO
For each EU presentation of a medicinal product for one Member State of destination having one or more official languages or for several Member States of destination having the same official language.
This fee covers any subsequent safety update notification relating to the initial notification triggered by a safety update adopted by the Committee for Medicinal Products for Human Use or the Committee for Veterinary Medicinal Products, which is identified and communicated by the Agency to the parallel distributor.

Annual update notification, manual check 650 EURO
For all changes made in one year from the anniversary of the initial notification to all the EU presentations belonging to the same pharmaceutical form of the same medicinal product having one or more official languages, or for several Member States of destination having the same official language.
This fee applies when a report generated by text comparison software has not been provided or has not met the specific conditions laid down by the Agency for the acceptance of the report.

Annual update notification, automated check 320 EURO
For all changes made in one year from the anniversary of the initial notification to all the EU presentations belonging to the same pharmaceutical form of the same medicinal product for one Member State of destination having one or more official languages, or for several Member States of destination having the same official language.
This fee applies when a report generated by text comparison software has been provided and has met the specific conditions laid down by the Agency for the acceptance of the report.
### Notification of changes, manual check

**650 EURO**

For each notification of changes that is not submitted as part of the annual update notification and is not a safety update.

This fee applies for each EU presentation of a medicinal product for one Member State of destination having one or more official languages, or for several Member States of destination having the same official language.

This fee applies when a report generated by text comparison software has not been provided or has not met the specific conditions laid down by the Agency for the acceptance of the report.

---

### Notification of changes, automated check

**320 EURO**

For each notification of changes that is not submitted as part of the annual update notification and is not a safety update.

This fee applies for each EU presentation of a medicinal product for one Member State of destination having one or more official languages, or for several Member States of destination having the same official language.

This fee applies when a report generated by text comparison software has been provided and has met the specific conditions laid down by the Agency for the acceptance of the report.

---

### Notification of bulk changes

**3 400 EURO**

For one or more changes that affect all of a parallel distributor’s initial notifications, at any point in time after the approval of the initial notification. The scope(s) of the changes are limited to: a change in the details of a parallel distributor (‘Change of name and/or address’ or ‘Reassignment of notices for Parallel Distribution’), addition or deletion of a re-packager, and/or a change in the name and/or address of a re-packager.

---

### 3.4. Worksharing procedures for variations to marketing authorisations

Refer to section 1.1.5 for details of administrative charges applicable to worksharing procedures under the terms of Article 20 of Commission Regulation (EC) No 1234/2008 and 2.1.5 for details of administrative charges applicable to worksharing procedures under the terms of Article 65 of Regulation (EU) 2019/6.
Fee determination and payment
4. Fee determination and payment

4.1. Legal requirements

Article 10 of Council Regulation (EC) No 297/95 stipulates the dates when fees are due and when they are payable.

Fee due date

The fee due date is the date when the Agency determines the total fee amount that is due for an application or service. The applicant’s or marketing authorisation holder’s obligation to pay that fee starts on that date.

The fee due date corresponds to:

- The date of administrative validation of an application; or
- The date of the start of a procedure (when there is no administrative validation), e.g. for type IA variation fees, transfer fees, Article 30(1) or 31 referrals; or
- The date of the anniversary of the notification of the marketing authorisation decision, for annual fees; or
- The date of the receipt of the inspection report, for inspection fees.

Note: For a change of applicant during an ongoing initial marketing authorisation application, any fee invoiced since validation (i.e. fee for initial marketing authorisation and pre-authorisation inspection fee) will be credited to the original applicant and re-invoiced to the new applicant. This includes changes, if any, relating to micro, small or medium-sized enterprise applicants and orphan medicinal product designation.

Payment of fees

The Agency’s terms and conditions for payment of fees stipulate that an invoice is payable 30 days from the invoice date. That represents the deadline for the applicant to settle the payment.

In summary, the procedure shown in Figure 1 applies.

Figure 1. Procedure for fee determination and payment
Deferred fees

Small or medium-sized enterprise (SME)

When the applicant is an SME, payment of the fee for a marketing authorisation (MA) application and the fee for inspections undertaken as part of the assessment of a MA application is deferred until the final decision (positive or negative outcome) on the MA is issued or the application is withdrawn. The invoice issued at the time the fee is due informs the applicant that the fee is deferred. A reminder is issued by the Agency as soon as there is a decision or withdrawal; the fee is payable within 45 days of the date of the notification of the final decision on the MA or of the withdrawal of the application.

A conditional fee exemption of the fee for the examination of a MA application is given where the scientific advice provided by EMA was taken into account by the applicant for the development of the product and a MA is not granted (due to negative outcome or withdrawal of the MA application). To benefit from a conditional fee exemption, the required criteria shall be valid on the fee due date. A subsequent change to the SME status (i.e. expiration of SME status) after the fee due date will not be taken into account.

The procedures are summarised in Figure 2.

Figure 2. Procedure for fee determination and payment by SME

Core dossier submission

The payment of the fee for an application for a MA of a medicinal product to be used in a human pandemic situation, so-called core dossier submission, is deferred until the pandemic situation is duly recognised, either by the World Health Organisation or the European Union, or up to 5 years from the due date, whichever comes first. Nevertheless, the deferral can come to an end earlier on withdrawal prior to an opinion on the MA application, or if a negative Commission Decision is issued. A reminder is issued by the Agency as soon as the deferral comes to an end and the fee is payable immediately.
4.2. **Criteria for fee determination**

The criteria that are taken into account by the Agency when determining the fee that is due are the ones that apply by the fee due date. These include:

- The applicant’s status (e.g. valid SME status assigned by the Agency);
- The product type (e.g. advanced therapy medicinal product, designated orphan product);
- The product status (e.g. in the first year following grant of a MA); and
- The procedure type.

Any change to the applicable criteria after the fee due date is not taken into account and will not influence the total fee due that has been determined.

4.3. **Established fee exemptions**

An applicant qualifies for fee exemptions and incentives specified in Chapter 5 provided that the required criteria apply on the fee due date. Any criterion that is no longer valid on the fee due date, e.g. expired SME status, cannot be taken into consideration by the Agency.

Applicants should ensure that they meet all the required criteria at the time of submission of an application or a request for a service.

4.4. **Request for ad hoc fee reduction**

Applicants may request the Executive Director to grant an ad hoc fee reduction under the provisions of the first paragraph of Article 9 of Council Regulation (EC) No 297/95.

The applicant is required to provide sufficient justification to prove that the request is made (1) in exceptional circumstances and (2) for imperative reasons of public or animal health. The request will be considered by the Executive Director, who will consult the competent scientific committee and will decide each request on a case-by-case basis.

In view of the administrative procedure that has to be followed and the mandatory scientific consultation, applicants are required to make their request in a letter to the Executive Director at least two months before the date of submission of the relevant application or two months before the anniversary of the European Birth date of the Marketing Authorisation for Annual fees. The applicant should cite Article 9, paragraph 1 of Council Regulation (EC) No 297/95 and provide details of the product, procedure type and applicable fee, and the reason(s) for the request that justify exceptional circumstances and imperative reasons of public or animal health.

Applicants are advised that late requests may not be processed in time and may not be taken into consideration when determining the fee.

Applicants are also advised that requests submitted after the receipt of an invoice will not be considered.

Further information on fees and fee exemptions is available on the Agency’s [website](#).
5. Fee exemptions

Where an applicant could, in respect of the same fee, benefit from more than one category of fee reduction or incentive (e.g. advanced therapy medicinal product, orphan medicinal product, micro, small or medium sized enterprises) the provisions which are the most favourable to the applicant would apply. The applicant can contact the Agency prior to submission of the application for confirmation of the applicable fee.

5.1. Micro, small or medium-sized enterprise

5.1.1. Definitions

Pursuant to Regulation (EC) No 2049/2005, Applicants that meet the definition of a micro, small or medium-sized enterprise are eligible for fee incentives from the Agency. Companies developing medicinal products for human and/or veterinary use can benefit from fee reductions, exemptions and/or deferrals, as applicable, under Articles 5 to 9 of Regulation (EC) No 2049/2005. Applicants must be established in the EEA and fulfil the definition of a micro, small or medium-sized enterprise as set out in Commission Recommendation 2003/361/EC of 6 May 2003.

5.1.2. Fee incentives

<table>
<thead>
<tr>
<th>Service</th>
<th>Fee Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific advice</td>
<td>90% reduction to the total applicable fee for non-orphan medicinal products</td>
</tr>
<tr>
<td></td>
<td>100% reduction to the total applicable fee for designated orphan medicinal products (see section 5.2.3)</td>
</tr>
<tr>
<td></td>
<td>100% reduction to the total applicable fee for products eligible to the PRIME scheme</td>
</tr>
<tr>
<td></td>
<td>90% reduction to the total applicable fee for veterinary medicinal products</td>
</tr>
<tr>
<td>Inspection (pre-authorisation)</td>
<td>90% reduction to the total applicable fee</td>
</tr>
<tr>
<td>Application for a marketing authorisation</td>
<td>Deferral of total applicable fee</td>
</tr>
<tr>
<td></td>
<td>Deferral of total applicable fee</td>
</tr>
<tr>
<td></td>
<td>Conditional fee exemption</td>
</tr>
<tr>
<td>Scientific services b</td>
<td>90% reduction to the total applicable fee for non-orphan medicinal products</td>
</tr>
<tr>
<td></td>
<td>100% reduction to the total applicable fee for designated orphan medicinal products (see section 5.2.3)</td>
</tr>
<tr>
<td>Establishment of maximum residue limit for a veterinary medicinal product</td>
<td>90% reduction to the total applicable fee</td>
</tr>
</tbody>
</table>
Fee exemptions

Extension or modification of maximum residue limit for a veterinary medicinal product | 90% reduction to the total applicable fee
---|---
Administrative services (excluding parallel distribution) | 100% reduction to the total applicable fee
Inspection (post-authorisation) | 90% reduction to the total applicable fee
Post-authorisation activities c | 100% reduction to the total applicable fee, in the case of micro enterprises

40% reduction to the total applicable fee, in the case of small or medium-sized enterprises

a Fee reduction is restricted to the development in the indication for which eligibility to the PRIME scheme was accepted.

b The fee reduction to the scientific service fee shall apply also to

- consultations on medical devices when the manufacturer has been assigned SME status by the Agency.
- veterinary medicinal product procedures with regards to Regulation (EU) 2019/6 classified as scientific service in accordance with heading 8 of Annex II to the Fee Regulation Implementing Rules.

c Defined as: extension of a marketing authorisation (medicines for human use); type-IA, type-IB or type-II variation (medicines for human use); renewal of a marketing authorisation (medicines for human use); transfer of a marketing authorisation from a micro, small or medium-sized enterprise; annual fee; referral procedure laid down in Article 30(1) or the first sub-paragraph of Article 31(1) of Directive 2001/83/EC initiated by the marketing authorisation holder).

5.2. Orphan medicinal products

5.2.1. Definitions

Total or partial exemptions from the payment of fees for applications for designated orphan medicinal products for human use shall be granted as laid down in a decision of the Executive Director on the use of the special contribution from the European Union, provided for by Article 7(2) of Regulation (EC) No 141/2000, reflecting the advice of the Committee for Orphan Medicinal Products.7

Applicants from the academic sector must be established in the EEA and fulfil the definition of public or private higher education establishments awarding academic degrees, public or private non-profit research organisations whose primary mission is to pursue research, or international European interest organisations as set out in Commission Regulation (EU) No 1290/2013 of 11 December 2013.

Applicants should not be financed or managed by private profit organisations in the pharmaceutical sector ("PPO"), nor should have they concluded any operating agreements with any PPO concerning their sponsorship or participation to the specific research project for which a fee exemption is sought.

These requirements shall be evidenced by a supporting declaration and documents which will be checked by the EMA upon receipt of a scientific advice request.

---

7 Executive Decision of 19 June 2020 (EMA/135645/2020)
5.2.2. Fee incentives for applicants other than micro, small and medium sized enterprises

<table>
<thead>
<tr>
<th>Service</th>
<th>Reduction to the total applicable fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol assistance (non-paediatric-related*) other than for academia</td>
<td>75%</td>
</tr>
<tr>
<td>Protocol assistance for academia</td>
<td>100%</td>
</tr>
<tr>
<td>Protocol assistance (paediatric-related*)</td>
<td>100%</td>
</tr>
<tr>
<td>Inspection (pre-authorisation)</td>
<td>100%</td>
</tr>
<tr>
<td>Application for a marketing authorisation</td>
<td>10%</td>
</tr>
</tbody>
</table>

* Paediatric-related protocol assistance is restricted to the development of an orphan medicinal product for the paediatric population, where the advice requested does not include the adult population.

5.2.3. Fee incentives for micro, small and medium sized enterprises

<table>
<thead>
<tr>
<th>Service</th>
<th>Reduction to the total applicable fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol assistance</td>
<td>100%</td>
</tr>
<tr>
<td>Scientific services**</td>
<td>100%</td>
</tr>
<tr>
<td>Inspection (pre-authorisation)</td>
<td>100%</td>
</tr>
<tr>
<td>Application for a marketing authorisation</td>
<td>100%</td>
</tr>
<tr>
<td>Post-authorisation activities, including annual fees, during the first year after marketing authorisation</td>
<td>100%</td>
</tr>
<tr>
<td>Inspection (post-authorisation)**</td>
<td>90%</td>
</tr>
</tbody>
</table>

** Fee reductions for scientific services and post-authorisation inspections are not funded by the special contribution from the European Union for designated orphan medicinal products but are provided for by Article 7 of Regulation (EC) No 2049/2005 on SMEs.

5.3. Multiple applications on usage patent grounds

5.3.1. Definitions

The full or partial exemptions from payment of fees described below are applicable for as long as the concerned marketing authorisation is affected by usage patent(s) pertaining to indication(s) and/or dosage form(s).
5.3.2. Fee incentives for an application for a marketing authorisation

5.3.2.1. Reduced fee (human medicinal products)

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Second and each subsequent multiple application submitted under Articles 10(1) and 10(3) of Directive 2001/83/EC</td>
<td>23 300 EURO</td>
</tr>
<tr>
<td>Second and each subsequent multiple application submitted under Article 10(4) of Directive 2001/83/EC</td>
<td>38 900 EURO</td>
</tr>
<tr>
<td>Additional strengths, pharmaceutical forms and presentations submitted at the same time as the aforementioned applications</td>
<td>100% reduction to the total applicable fee</td>
</tr>
</tbody>
</table>

5.3.2.2. Reduced fee (veterinary medicinal products)

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Second and each subsequent multiple application submitted under Articles 18 and 19 (except products specified below) of Regulation (EU) 2019/6 solely on usage patent grounds</td>
<td>15 400 EURO</td>
</tr>
<tr>
<td>Second and each subsequent multiple application submitted for similar biological veterinary medicinal products submitted under Articles 19 of Regulation (EU) 2019/6 solely on usage patent grounds</td>
<td>28 100 EURO</td>
</tr>
<tr>
<td>Second and each subsequent multiple application submitted for veterinary immunological medicinal products solely on usage patent grounds</td>
<td>15 400 EURO</td>
</tr>
<tr>
<td>Additional strengths, pharmaceutical forms and presentations submitted at the same time as the aforementioned applications</td>
<td>100% reduction to the total applicable fee</td>
</tr>
</tbody>
</table>

5.3.3. Fee incentives for post-authorisation activities for a second and for each subsequent multiple application

5.3.3.1. Reduced fee (human medicinal products)

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extension of a marketing authorisation</td>
<td>22 400 EURO</td>
</tr>
<tr>
<td>Additional strengths and presentations of the same pharmaceutical form submitted at the same time as the aforementioned application</td>
<td>100% reduction to the total applicable fee</td>
</tr>
<tr>
<td>Description</td>
<td>Fee</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Type-IA variation to a marketing authorisation. This fee shall only apply in the case of grouping of the same type-IA variations to the terms of multiple marketing authorisations on usage patent grounds owned by the same holder (as defined in Article 7(2)(a) of Commission Regulation (EC) No 1234/2008). The applicable fee shall be payable for each individual type-IA variation relating to the second and each of the subsequent multiple marketing authorisations in the grouping</td>
<td>650 EURO</td>
</tr>
<tr>
<td>Worksharing procedure under the terms of Article 20 of Commission Regulation (EC) No 1234/2008. Administrative fees for variations to multiple centralised marketing authorisations on usage patent grounds</td>
<td>Refer to section 1.1.5.2.</td>
</tr>
<tr>
<td>Renewal of a marketing authorisation</td>
<td>3 000 EURO</td>
</tr>
<tr>
<td>Additional strengths associated with a pharmaceutical form submitted at the same time as the aforementioned application</td>
<td>100% reduction to the total applicable fee</td>
</tr>
<tr>
<td>Annual fee for a marketing authorisation granted under Articles 10(1) and 10(3) of Directive 2001/83/EC</td>
<td>5 400 EURO</td>
</tr>
<tr>
<td>Annual fee for a marketing authorisation granted under Article 10(4) of Directive 2001/83/EC</td>
<td>10 700 EURO</td>
</tr>
<tr>
<td><strong>5.3.3.2. Reduced fee (veterinary medicinal products)</strong></td>
<td></td>
</tr>
<tr>
<td>Second and each subsequent multiple application submitted solely on usage patent grounds for variation requiring assessment specified in sub-section 2.1.4.1 of marketing authorisations granted under Articles 18 and 19 of Regulation (EU) 2019/6</td>
<td>7 840 EURO</td>
</tr>
<tr>
<td>Additional strengths and presentations of the same pharmaceutical form submitted at the same time as the aforementioned application</td>
<td>100% reduction to the total applicable fee</td>
</tr>
<tr>
<td>Worksharing procedure under the terms of Article 65 of Regulation (EU) 2019/6. Administrative fees for variations to multiple centralised marketing authorisations on usage patent grounds</td>
<td>Refer to section 2.1.5.2.</td>
</tr>
</tbody>
</table>
Annual fee for a marketing authorisation granted under Articles 18 and 19 (except products specified below) of Regulation (EU) 2019/6 | 1 870 EURO
---|---
Annual fee for a marketing authorisation granted under Article 19 of Regulation (EU) 2019/6 for similar biological veterinary medicinal products | 3 890 EURO

### 5.4. Medicinal products for paediatric use

#### 5.4.1. Definitions

A partial exemption from the payment of the fees laid down in the fee regulation is granted for paediatric use marketing authorisation applications (PUMAs) submitted under Article 30 of Regulation (EC) No 1901/2006 on medicinal products for paediatric use.

A total exemption from the payment of the fees laid down in the fee regulation is granted for scientific advice provided by the Agency to sponsors developing medicinal products for the paediatric population as laid down in Regulation (EC) No 1901/2006 on medicinal products for paediatric use.

#### 5.4.2. Fee incentives for paediatric use marketing authorisations (PUMAs)

<table>
<thead>
<tr>
<th>Application for a paediatric use marketing authorisation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inspection (pre-authorisation)</td>
<td></td>
</tr>
</tbody>
</table>

During the first year after marketing authorisation for:
- extension of a marketing authorisation;
- type-IA, type-IB and type-II variations;
- annual fee;
- inspection (post-authorisation).

50\% reduction to the total applicable fee

#### 5.4.3. Fee incentives for scientific advice

Scientific advice on the development of a medicinal product for the paediatric population (when the advice requested does not include the adult population)

100\% reduction to the total applicable fee

### 5.5. Advanced therapy medicinal products

#### 5.5.1. Definitions

Total or partial exemptions from the payment of fees for applications for advanced therapy medicinal products for human use are granted as laid down in Articles 16(2) of Regulation (EC) No 1394/2007.
5.5.2. Fee incentives for applicants other than micro, small and medium-sized enterprises

| Scientific advice | 65% reduction to the total applicable fee |

5.5.3. Fee incentives for micro, small and medium-sized enterprises

| Scientific advice | 90% reduction to the total applicable fee (see section 5.1.2) |

5.6. Core dossier medicinal products to be used in a human pandemic situation

5.6.1. Definitions

A total exemption from the payment of the fees laid down in the fee regulation is granted for the regulatory activities specified below within the framework of the submission of a core dossier for a pandemic influenza vaccine and the follow-up submission of a pandemic variation, as described in the 'Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application' (EMEA/CPMP/VEG/4717/03).

The following total exemptions apply until the type II pandemic variation, submitted once the human pandemic situation is duly recognised, has been authorised by the European Union.

5.6.2. Fee incentives related to pandemic core dossier (including informed consent) for 'non-recognised' strain

| Scientific advice | 100% reduction to the total applicable fee |
| Post-authorisation activities including type-IA, type-IB, type-II variations (but excluding the type-II pandemic variation) and annual fee | 100% reduction to the total applicable fee |
| Negative validation of a type-IB or type-II variation (but excluding the type-II pandemic variation) | 100% reduction to the total applicable fee |

- The fee for a validated pandemic core dossier marketing authorisation application (MAA), including informed consent application, for a pandemic strain that has not yet been "duly recognised, either by the World Health Organisation or by the Community” is deferred.
- If the core dossier MAA is withdrawn prior to opinion or receives a negative Commission Decision, the fee becomes payable and the deferral comes to an end.
- If the core dossier receives a positive Commission Decision, the fee shall continue to be deferred. The MAH also receives fee reductions on variations and annual fees.
- When the pandemic situation becomes duly recognised, the marketing authorisation holder (MAH) may choose not to submit a Type II pandemic variation. In this case the MAA fee continues to be deferred for up to 5 years from the MAA validation date. The MAH continues to receive fee reductions on variations and annual fees.
• If the MAH chooses to submit a Type II pandemic variation, the initial MAA fee becomes payable on the first submission made as part of the rolling review. When the Type II pandemic variation is validated the applicable Type II fee becomes payable. The MAH continues to receive fee reductions on variations and annual fees until the date of the Type II Commission Decision.

• Fee reductions for scientific advice are applicable to requests in the context of a pandemic core dossier and at any time from the MAA validation date up to the date of the Type II Commission Decision.

• The fee for an emergency pandemic MAA submitted when the pandemic situation has been duly recognised becomes payable on validation.

**Figure 3.** Schematic overview of pandemic vaccine fee reductions, deferrals and payments

### 5.7. Veterinary medicinal products for limited markets

#### 5.7.1. Definitions

A total or partial exemption of the fee shall apply for veterinary medicinal products classified as eligible for consideration under Article 23 of Regulation (EU) 2019/6 as referred to in section 2.4.

#### 5.7.2. Fee incentives

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scientific advice</strong></td>
<td><strong>50% reduction to the total applicable fee</strong></td>
</tr>
<tr>
<td><strong>Extension of maximum residues limit involving no</strong></td>
<td><strong>100% reduction to the total applicable fee</strong></td>
</tr>
</tbody>
</table>
5.8. Deleted

5.9. Veterinary vaccines against certain epizootic diseases

5.9.1. Definitions

A total exemption from the payment of the fees laid down in the fee regulation is granted for certain post-authorisation activities in relation to vaccines against:

- bluetongue
- pandemic avian influenza
- foot and mouth disease
- classical swine fever

for which

- the vaccine is authorised under normal circumstances and
- the product has not been marketed within the EU/EEA at any time during the totality of the period covered by the fee.

5.9.2. Fee incentives

| Annual fee | 100% reduction to the total applicable fee |

5.10. Scientific advice for PRIME scheme

5.10.1. Definitions

A total exemption from the payment of the fees laid down in the fee regulation is granted for requests for scientific advice and follow-up requests submitted on products eligible to PRIME scheme for SMEs and applicants of the academic sector.

Applicants from the academic sector must be established in the EEA and fulfil the definition of public or private higher education establishments awarding academic degrees, public or private non-profit research organisations whose primary mission is to pursue research, or international European interest organisations as set out in Commission Regulation (EU) No 1290/2013 of 11 December 2013.

Applicants should not be financed or managed by private profit organisations in the pharmaceutical sector ("PPO"), nor should have they concluded any operating agreements with any PPO concerning their sponsorship or participation to the specific research project for which a fee exemption is sought.
These requirements shall be evidenced by a supporting declaration and documents which will be checked by the EMA upon receipt of a scientific advice request.

5.10.2. Fee incentives

<table>
<thead>
<tr>
<th>Scientific advice</th>
<th>100% reduction to the total applicable fee*, in the case of micro, small or medium sized enterprises</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100% reduction to the total applicable fee*, in the case of applicants from the academic sector</td>
</tr>
</tbody>
</table>

* Fee reduction is restricted to the development in the indication for which eligibility to the PRIME scheme was accepted.

5.11. Vaccines authorised under exceptional circumstances for preparedness against biological agents

5.11.1. Definition

A partial exemption from the payment of the fees laid down in the fee regulation is granted for certain post-authorising activities in relation to vaccines authorised under exceptional circumstances for preparedness against biological agents that might be used as weapons of bio-terrorism as detailed in the EMA/CHMP Guidance document on use of medicinal products for the treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism.⁸

5.11.2. Fee incentives

<table>
<thead>
<tr>
<th>Annual fee</th>
<th>50% reduction to the total applicable fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type-IA, type-IB and type-II variations</td>
<td>50% reduction to the total applicable fee</td>
</tr>
<tr>
<td>Renewal of marketing authorisation</td>
<td>50% reduction to the total applicable fee</td>
</tr>
<tr>
<td>Extension of a marketing authorisation</td>
<td>50% reduction to the total applicable fee</td>
</tr>
<tr>
<td>Transfer of a marketing authorisation</td>
<td>50% reduction to the total applicable fee</td>
</tr>
</tbody>
</table>

5.12. Scientific advice on clinical trial protocols pursuant to Article 16(2) of Regulation 2022/123

5.12.1. Definition

A total exemption from the payment of the fees laid down in the fee regulation is granted for certain scientific advice on clinical trial protocols for medicinal products with the potential to address a public health emergency pursuant to Article 16(2) of Regulation 2022/123.

---

⁸ CPMP/4048/01 16.01.2002 as last amended; i.e. anthrax, plague, tularemia, smallpox, viral haemorrhaging fever, botulism, brucellosis, Q-fever, glanders and melioidosis and other infectious diseases
### 5.12.2. Fee incentives

| Scientific advice for clinical protocol | 100% reduction to the total applicable fee |
Annex
Annex

The additional information in this annex is listed using the same numbering as the corresponding sections in chapters 1 to 4. For example, section A.1.1.2. in this annex relates to section 1.1.2. in Chapter 1.

A.1. Medicinal products for human use

A.1.1.2. Examples of the determination of fees for applications for marketing authorisation

It should be noted that the calculation of the total fee for a marketing authorisation application is driven by the pharmaceutical forms, the associated strengths and the associated presentations. The examples shown below do not represent an exhaustive list.

Scenario 1:
Full dossier application for a medicinal product having one pharmaceutical form with one strength and X presentations

![Diagram]

- **Product**
  - **Form 1**
  - **Strength 1**
  - **Presentation 1**
  - **Presentation 2**
  - **Presentation X**

**Basic fee**
313 200 EURO
Includes one pharmaceutical form and one associated strength and one presentation.

**Additional fee**
+ (X-1)*7 800 EURO
For additional presentations associated with the single strength.
**Scenario 2:**

Full dossier application for a medicinal product having two pharmaceutical forms with two strengths and X presentations/ strength associated with the first form and one strength and Y presentations associated with the second form.

- **Basic fee**
  - 313 200 EURO
  - Includes one pharmaceutical form and one associated strength and one presentation.

- **Additional fee**
  - (+ (X-1)*7 800 EURO)
  - For additional presentations associated with the first form and strength.

- **Additional fee**
  - + 31 500 EURO
  - Second strength associated with the first form including one presentation.

- **Additional fee**
  - (+ (X-1)*7 800 EURO)
  - For additional presentations associated with the first form and second strength.

- **Additional fee**
  - + 31 500 EURO
  - Second form including its associated strength and one presentation.

- **Additional fee**
  - (+ (Y-1)*7 800 EURO)
  - For additional presentations associated with the second form and its strength.
Scenario 3:
Full dossier application for an insulin product having two pharmaceutical forms with six strengths (consisting of two sets of one uncombined preparation and two combination preparations (having different proportions of insulin) with insulin amounts corresponding to A I.U. and B I.U.) and X presentations/strength associated with the first form; and two strengths (of un-combined preparations with insulin amounts corresponding to A I.U. and B I.U.) and Y presentations/strength associated with the second form.

(u) = un-combined insulin preparation
(c) = combination insulin preparation (refer to section 1.1.1 for definition of strength of insulin products)

**313 200 EURO**
Includes one pharmaceutical form and one associated strength and one presentation.

**+ (X-1)* 7 800 EURO**
For additional presentations associated with the first form and strength.

**+ 5*31 500 EURO**
For second to sixth strengths associated with the first form including one...
<table>
<thead>
<tr>
<th>Additional fee</th>
<th>Presentation for each strength.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$5 \times (X - 1) \times 7800$</td>
</tr>
<tr>
<td>Additional fee</td>
<td>Additional presentations associated with the second to sixth strengths of the first form.</td>
</tr>
<tr>
<td></td>
<td>$31,500$ EURO</td>
</tr>
<tr>
<td>Additional fee</td>
<td>Second form including one associated strength and one presentation.</td>
</tr>
<tr>
<td></td>
<td>$Y \times 7800$ EURO</td>
</tr>
<tr>
<td>Additional fee</td>
<td>For additional presentations associated with the second form and first strength.</td>
</tr>
<tr>
<td></td>
<td>$31,500$ EURO</td>
</tr>
<tr>
<td>Additional fee</td>
<td>Second strength associated with the second form including one presentation.</td>
</tr>
<tr>
<td></td>
<td>$X \times 7800$ EURO</td>
</tr>
<tr>
<td>Additional fee</td>
<td>For additional presentations associated with the second form and second strength.</td>
</tr>
</tbody>
</table>
Scenario 4:

Full dossier application with 3 strengths, e.g. 100mg, 200mg and 300mg. The 100 and 200mg strengths will be packaged together in a starter pack and the 300mg strength will have two presentations. The 100 and 200mg strengths do not have additional presentations.

<table>
<thead>
<tr>
<th>Product Form 1</th>
<th>Strength 1</th>
<th>Presentation Starterpack</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Strength 2</td>
<td>Presentation 1</td>
</tr>
<tr>
<td></td>
<td>Strength 3</td>
<td>Presentation 2</td>
</tr>
</tbody>
</table>

**313 200 EURO**

Basic fee

Includes one pharmaceutical form and one associated strength and the starter pack presentation.

**+ 2*31 500 EURO**

Additional fee

For second and third strengths associated with the first form including presentation 1 for the 3rd strength.

**+ 1* 7 800 EURO**

Additional fee

Additional presentation 2 associated with the third strength of the first form.
A.1.1.3. Examples of the determination of fees for extensions of marketing authorisation

It should be noted that the basic fee for an extension of a marketing authorisation is driven by the pharmaceutical form. The examples shown below do not represent an exhaustive list.

**Scenario 1:**
New pharmaceutical form with two strengths and X presentations/strength, for authorised or new route of administration (with submitted/cross-referenced clinical data)

**Extension application:**
- One pharmaceutical form, first strength and X presentations
- Second strength (of same new pharmaceutical form) and X presentations

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>94 000 EURO</td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ (X-1)*7 800 EURO</td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ 23 700 EURO</td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ (X-1)*7 800 EURO</td>
</tr>
</tbody>
</table>

**Scenario 2:**
New route of administration for authorised pharmaceutical form with two authorised strengths and X presentations/strength (with submitted/cross-referenced clinical data)

**Extension application:**
- Route of administration for authorised pharmaceutical form, first strength and X presentations
- Second strength (same new route of administration for same authorised pharmaceutical form) and X presentations

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>94 000 EURO</td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ (X-1)*7 800 EURO</td>
</tr>
</tbody>
</table>

Additional fee

+ 23 700 EURO
For additional strength fee.

+ (X-1)*7 800 EURO
For additional presentation fees.

**Scenario 3:**

Two new strengths of same authorised pharmaceutical form and X presentations/strength (without submitted/cross-referenced clinical data)

*Extension application:*

- First new strength and X presentations
- Second new strength (of same authorised pharmaceutical form) and X presentations

70 600 EURO
For extension.

+ (X-1)*7 800 EURO
For additional presentation fees.

+ 23 700 EURO
For additional strength fee.

+ (X-1)*7 800 EURO
For additional presentation fees.

**Scenario 4:**

One new strength of each of two authorised pharmaceutical forms and X presentations/strength (without submitted/cross-referenced clinical data)

*This constitutes as two extension applications*

*Extension application 1:*

- New strength (of first authorised pharmaceutical form) and X presentations

70 600 EURO
For extension.

+ (X-1)*7 800 EURO
Additional fee  For additional presentation fees.

**Extension application 2:**
- New strength (of second authorised pharmaceutical form) and X presentations

  70 600 EURO  
  Basic fee  For extension.

+ (X-1)*7 800 EURO  
Additional fee  For additional presentation fees.

**Scenario 5:**
New strength for an authorised pharmaceutical form and route of administration and X presentations AND new pharmaceutical form associated with a new strength and new route of administration and X presentations (with submitted/cross-referenced clinical data)

This constitutes as two extension applications

**Extension application 1:**
- New strength for an authorised pharmaceutical form and route of administration and X presentations (with submitted/cross-referenced clinical data)

  94 000 EURO  
  Basic fee  For extension.

+ (X-1)*7 800 EURO  
Additional fee  For additional presentation fees

**Extension application 2:**
- New pharmaceutical form associated with new (first) strength and new route of administration and X presentations

  94 000 EURO  
  Basic fee  For extension.

+ (X-1)* 7 800 EURO  
Additional fee  For additional presentation fees

**Scenario 6:**
New pharmaceutical form associated with new route of administration for two new strengths and X presentations/strength (with submitted/cross-referenced clinical data) AND two new strengths for
an authorised pharmaceutical form and route of administration and X presentations/strength (without submitted/cross-referenced clinical data)

This constitutes as two extension applications

**Extension application 1:**

- New pharmaceutical form associated with new route of administration for first strength and X presentations (with clinical data)
- Second strength (same new pharmaceutical form associated with same new route of administration) and X presentations

94 000 EURO
Basic fee
For extension.

+ (X-1)*7 800 EURO
Additional fee
For additional presentation fees

+ 23 700 EURO
Additional fee
For additional strength fee

+ (X-1)*7 800 EURO
Additional fee
For additional presentation fees

**Extension application 2:**

- First new strength of authorised pharmaceutical form and route of administration and X presentations (without clinical data)
- Second strength (of same authorised pharmaceutical form and route of administration) and X presentations

70 600 EURO
Basic fee
For extension.

+ (X-1)*7 800 EURO
Additional fee
For additional presentation fees

+ 23 700 EURO
Additional fee
For additional strength fee

+ (X-1)*7 800 EURO
Additional fee
For additional presentation fees
A.1.1.4. Examples of the determination of fees for variations to a marketing authorisation introducing new presentations (i.e. EU sub-numbers)

It should be noted that the calculation of the total fee is determined by the number and type of variations (IA, IB).

Each new presentation requested (i.e. each new EU sub-number) should be submitted as a single variation attracting a separate fee (i.e. x additional presentations = x variations = x separate fees).

The type of variation (IA or IB) is determined by the currently approved range of pack sizes for each strength and pharmaceutical form. Range is defined from the smallest to the biggest approved pack size (not from '0') for the same pharmaceutical form and strength. The pack size equals to the number of units of the pharmaceutical form (e.g. tablets, sachets, ampoules, etc.) contained per outer packaging. Pack sizes not included within this range are considered to be outside of the range.

- For the addition of a new pack size where the number of units of the pack is within the range of the currently approved pack sizes for the strength and pharmaceutical form, applicants should submit a variation B.II.e.5.a).1 (IA).

- For the addition of a new pack size where the number of units of the pack is outside the range of the currently approved pack sizes for the strength and pharmaceutical form, applicants should submit a variation B.II.e.5.a).2 (IB).

In support of a timely introduction of new pack sizes to the market, EMA accepts the following approach for the introduction of various pack sizes falling outside the range within a single grouped submission. The biggest or the smallest pack size per strength outside the range should be classified as B.II.e.5.a).2 (IB). This presentation defines the new limits of the range so that any intermediate pack size for the strength and pharmaceutical form can be classified as B.II.e.5.a).1 (IA).

The example shown below does not represent an exhaustive list.

**Scenario 1:**

Addition of two new pack-sizes (pack-sizes 6 and 10) to each of the two strengths for a marketing authorisation with a currently approved pack-size of 4 authorised for each strength.

**3 500 EURO**

Basic fee

For a minor variation to a marketing authorisation, as defined in Article 2(2) of the Commission Regulation (EC) No 1234/2008 (type IA).

**7 800 EURO**

Basic fee

For a minor variation to a marketing authorisation, as defined in Article 2(5) of the Commission Regulation (EC) No 1234/2008 (type IB).
The addition of the 4 new pack sizes in the example above should be submitted as a grouping of 4 variations (2 x Type IA + 2 x Type IB).

Fee payable: 2 Type IA fees + 2 Type IB fees, i.e. 2 x 3 500 EURO + 2 x 7 800 EURO = 22 600 EURO
A.1.1.6. Examples of the determination of fees for renewals of marketing authorisation

It should be noted that the number of renewal fees charged for a medicinal product depends on the number of strengths associated with each pharmaceutical form determined as shown in section A.1.1.2. The number of presentations is not taken into consideration for the calculation of the renewal fee. The examples shown below do not represent an exhaustive list.

**Scenario 1:**
Full dossier application for a medicinal product having one pharmaceutical form with one strength and X presentations

*Strengths associated with a pharmaceutical form:*
- One strength associated with one pharmaceutical form

<table>
<thead>
<tr>
<th>Basic fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 400 EURO</td>
</tr>
</tbody>
</table>

For renewal.

**Scenario 2:**
Full dossier application for a medicinal product having two pharmaceutical forms with two strengths and X presentations/strength associated with the first form and one strength and Y presentations associated with the second form.

*Strengths associated with a pharmaceutical form:*
- Two strengths associated with first pharmaceutical form
- One strength associated with second pharmaceutical form

<table>
<thead>
<tr>
<th>Basic fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>2*15 400 EURO</td>
</tr>
</tbody>
</table>

For renewal.

<table>
<thead>
<tr>
<th>Additional fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>+ 15 400 EURO</td>
</tr>
</tbody>
</table>

For renewal.
**Scenario 3:**

Full dossier application for an insulin product having two pharmaceutical forms with six strengths (consisting of two sets of one un-combined preparation and two combination preparations (having different proportions of insulin) with insulin amounts corresponding to A I.U. and B I.U.) and X presentations/strength associated with the first form; and two strengths (of un-combined preparations with insulin amounts corresponding to A I.U. and B I.U.) and Y presentations/strength associated with the second form

**Strengths associated with a pharmaceutical form:**

- Six strengths associated with first pharmaceutical form
- Two strengths associated with second pharmaceutical form

\[
\begin{align*}
\text{Basic fee} & \quad 6 \times 15400 \text{ EURO} \\
& \quad \text{For renewal.} \\
\text{Additional fee} & \quad + 2 \times 15400 \text{ EURO} \\
& \quad \text{For renewal.}
\end{align*}
\]
A.1.1.7.1. Examples of the determination of fees for GMP inspections

In accordance with Annex IV to the “Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures”, applicants are liable for more than one inspection fee on the basis of the following flowchart.

The examples shown below do not represent an exhaustive list. They apply to good manufacturing practice (GMP) inspections in relation to medicines for human use and to medicines for veterinary use.
Scenario 1:

GMP inspection of manufacturing site 1 for one medicinal product A and involving two pharmaceutical forms: capsules (non-sterile) and solution for injection (sterile). The manufacturing activity for the two pharmaceutical forms is the same, i.e. manufacture of the finished product.

Fee payable: 2 basic fees (level I), i.e. 23 700 EURO + 23 700 EURO = 47 400 EURO

Rationale: there are two types of dosages forms (sterile and non-sterile) and each one attracts a basic fee (Level I).

The applicable fees to be paid are represented by the blue boxes in the flowchart below.
Scenario 2:

GMP inspection of manufacturing site 1 for two medicinal products (A and B). Product A involves only one pharmaceutical form (capsules) and one pharmaceutical activity (primary packaging). Product B also involves one pharmaceutical form (tablets) and four manufacturing activities (manufacture of the active substance, quality control of the active substance, manufacture of the finished product and primary packaging).

Fee payable: 3 basic fees (Level I), i.e. 23 700 EURO + 23 700 EURO + 23 700 EURO = 71 100 EURO; the applicable fees to be paid are represented by the blue boxes in the flowchart below.

Rationale: Product A attracts only one fee because there is only one group of manufacturing activities (i.e. finished product) and one dosage form (non-sterile). Product B attracts two fees because there are manufacturing activities related to each group as follows:

- Group Active Substance: manufacture of the active substance and quality control of the active substance
- Group Finished Product: manufacture of the finished product and Primary Packaging
A.1.1.7.2. Examples of the determination of fees for GCP inspections

In accordance with Annex IV to the "Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures", applicants are liable for more than one inspection fee on the basis of the following flowchart.

The examples shown below do not represent an exhaustive list. They apply to good clinical practice (GCP) inspections in relation to medicines for human use and to medicines for veterinary use.
**Scenario 1:**

GCP inspection request for Product A marketing authorisation application and the conduct of clinical trial protocol A at Site A (investigator site) for one clinical trial activity (Activity Group I) and at site B (sponsor site) for two clinical trial activities (Activity Group III and Activity Group IV). GCP inspection of clinical trial protocol B conducted at site C (Central laboratory) for one activity group (Activity group II);

Fee payable: 4 basic fees, i.e. 23 700 EURO + 23 700 EURO + 23 700 EURO + 23 700 EURO = 94 800 EURO;

Rationale: there is one product A supported by two pivotal trials the conduct of which is inspected for clinical trial protocol A at Site A for one activity group (Activity Group I) and at site B for two activity Groups (Activity group III and Activity Group IV). The clinical trial protocol B is inspected at site C for one activity group (Activity Group II) and each activity group attracts a basic fee (Level I).
**Scenario 2:**

GCP inspection request for Product A marketing authorisation application and the conduct of clinical trial protocol B at Site C (i.e. CRO site including clinical and bioanalytical facility) for two clinical trial activities (Activity Group I) and (Activity Group II).

Fee payable: 2 basic fees, i.e. 23 700 EURO + 23 700 EURO = 47 400 EURO

Rationale: there is one product A supported by one pivotal trial the conduct of which is inspected for clinical trial protocol B at Site C for two activity groups (Activity Group I and Activity Group II) and each activity group attracts a basic fee (Level I).
A.1.4.3 Examples of the determination of fees for applications for companion diagnostics devices

Scenario 1:
Initial request for a consultation on the suitability of a companion diagnostic for Product A containing active substance 1 and product B containing same active substance

Fee payable: one basic fee, i.e., 44 400 EUR
**Scenario 2:**

Initial request for a consultation on the suitability of a companion diagnostic with medicinal product A containing active substance 1 and medicinal product B containing a combination of active substances 1 and 2 and medicinal product C containing active substance 2

Fee payable: one basic fee and one additional fee per active substance, i.e., 44 400 EUR + 7 400 EUR + 7 400 EUR = 59 200 EUR
A.2. Veterinary medicinal products

A.2.1.2. Examples of the determination of fees for applications for marketing authorisation

It should be noted that the calculation of the total fee for a marketing authorisation application is driven by the pharmaceutical forms, the associated strengths and the associated presentations. The number of target species is irrelevant. The examples shown below do not represent an exhaustive list.

**Scenario 1:**

Full dossier application for a medicinal product having one pharmaceutical form with one strength and X presentations

- **Basic fee:** 156 700 EURO
  - Includes one pharmaceutical form and one associated strength and one presentation.

- **Additional fee:** \((X-1)\times7 800\) EURO
  - For additional presentations associated with the single strength.
Scenario 2:

Full dossier application for a medicinal product having two pharmaceutical forms with two strengths and X presentations/strength associated with the first form and one strength and Y presentations associated with the second form.

**Basic fee**: 156,700 euros

- Includes one pharmaceutical form and one associated strength and one presentation.

**Additional fee**: (+ (X-1) \* 7,800 euros)

- For additional presentations associated with the first form and strength.

**Additional fee**: + 15,400 euros

- Second strength associated with the first form including one presentation.

**Additional fee**: (+ (X-1) \* 7,800 euros)

- For additional presentations associated with the first form and second strength.

**Additional fee**: + 15,400 euros

- Second form including its associated strength and one presentation.

**Additional fee**: (+ (Y-1) \* 7,800 euros)

- For additional presentations associated with the second form and its strength.
A.2.1.4. Examples of the determination of fees for VRA level 1 of marketing authorisation

It should be noted that the basic fee for a VRA level 1 of a marketing authorisation is driven by the pharmaceutical form. The examples shown below do not represent an exhaustive list.

**Scenario 1:**
New pharmaceutical form with two strengths and X presentations/strength, for authorised or new route of administration (with submitted/cross-referenced clinical data)

**VRA level 1 application:**
- One pharmaceutical form, first strength and X presentations
- Second strength (of same new pharmaceutical form) and X presentations

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>39 200 EURO</td>
</tr>
<tr>
<td>For VRA Level 1</td>
<td></td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ (X-1)*7 800 EURO</td>
</tr>
<tr>
<td>For additional presentation fees.</td>
<td></td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ 9 700 EURO</td>
</tr>
<tr>
<td>For additional strength fee.</td>
<td></td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ (X-1)*7 800 EURO</td>
</tr>
<tr>
<td>For additional presentation fees.</td>
<td></td>
</tr>
</tbody>
</table>

**Scenario 2:**
New route of administration for authorised pharmaceutical form with two authorised strengths and X presentations/strength (with submitted/cross-referenced clinical data)

**VRA level 1 application:**
- Route of administration for authorised pharmaceutical form, first strength and X presentations
- Second strength (same new route of administration for same authorised pharmaceutical form) and X presentations

<table>
<thead>
<tr>
<th>Description</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fee</td>
<td>39 200 EURO</td>
</tr>
<tr>
<td>For VRA Level 1</td>
<td></td>
</tr>
<tr>
<td>Additional fee</td>
<td>+ (X-1)*7 800 EURO</td>
</tr>
<tr>
<td>For additional presentation fees.</td>
<td></td>
</tr>
</tbody>
</table>

Additional fee
+ 9 700 EURO
For additional strength fee.

Additional fee
+ (X-1)*7 800 EURO
For additional presentation fees.

**Scenario 3:**

Two new strengths of same authorised pharmaceutical form and X presentations/strength (without submitted/cross-referenced clinical data)

**VRA level 1 application:**

- First new strength and X presentations
- Second new strength (of same authorised pharmaceutical form) and X presentations

**35 400 EURO**
For VRA Level 1.

Additional fee
+ (X-1)* 7 800 EURO
For additional presentation fees.

Additional fee
+ 9 700 EURO
For additional strength fee.

Additional fee
+ (X-1)* 7 800 EURO
For additional presentation fees.
**Scenario 4:**

One new strength of each of two authorised pharmaceutical forms and X presentations/strength (without submitted/cross-referenced clinical data)

**THESE SHOULD BE SUBMITTED AS SEPARATE VRA LEVEL 1 APPLICATIONS:**

**VRA level 1 application 1:**

- New strength (of first authorised pharmaceutical form) and X presentations

  **35 400 EURO**  
  Basic fee
  
  For VRA Level 1.

  **+ (X-1)*7 800 EURO**  
  Additional fee
  
  For additional presentation fees.

**VRA level 1 application 2:**

- New strength (of second authorised pharmaceutical form) and X presentations

  **35 400 EURO**  
  Basic fee
  
  For VRA Level 1.

  **+ (X-1)*7 800 EURO**  
  Additional fee
  
  For additional presentation fees.

**VRA level 1 application 3:**

- New pharmaceutical form for new target species, first strength and X presentations

  **39 200 EURO**  
  Basic fee
  
  For VRA Level 1.

  **+ (X-1)*7 800 EURO**  
  Additional fee
  
  For additional presentation fees.

  **+ 9 700 EURO**  
  Additional fee
  
  For additional strength fee.

  **+ (X-1)*7 800 EURO**  
  Additional fee
  
  For additional presentation fees.
**VRA level 1 application 4:**

- New pharmaceutical form for a new target species, one strength and X presentations

  $39\,200\,\text{EURO}$
  
  Basic fee
  
  For VRA Level 1.

  $+(X-1)\times7\,800\,\text{EURO}$
  
  Additional fees
  
  For additional presentation fees.

**VRA level 1 application 5:**

- Second new target species of authorised pharmaceutical form, new strength and X presentations
- Second strength (for same new target species of authorised pharmaceutical form) and X presentations

  $39\,200\,\text{EURO}$
  
  Basic fee
  
  For VRA Level 1.

  $+(X-1)\times7\,800\,\text{EURO}$
  
  Additional fees
  
  For additional presentation fees.

  $+9\,700\,\text{EURO}$
  
  Additional fee
  
  For additional strength fee.

  $+(X-1)\times7\,800\,\text{EURO}$
  
  Additional fees
  
  For additional presentation fees.
A.3. Administrative fees

A.3.2. Examples of the determination of fees for certificates of medicinal product

In accordance with Annex III of the “Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures”, requesters are liable for more than one fee depending on the number of medicinal products, importing countries, languages and annexes.

The examples shown below do not represent an exhaustive list.

Scenario 1:
One request for certificates for one medicinal product, as follows:
- Addressed to country 1: 5 certificates with annex 1
- Addressed to country 2: 10 certificates with annex 1

Fee payable using the standard procedure: **620 EURO**

- **320 EURO**
  For the first set of 5 certificates for country 1.

- **+ 160 EURO**
  For the second set of maximum 6 out of 10 certificates for country 2.

- **+ 160 EURO**
  For the third set of 4 out of 10 certificates for country 2.

Fee payable using the urgent procedure: **1 920 EURO**

- **960 EURO**
  For the first set of 5 certificates for country 1.

- **+ 480 EURO**
  For the second set of maximum 6 out of 10 certificates for country 2.

- **+ 480 EURO**
  For the third set of 4 out of 10 certificates for country 2.

The applicable fees to be paid using the standard procedure are represented in the flowchart below.
Scenario 2:

One request for certificates for two medicinal products, as follows:

- **Medicinal product A:**
  - Addressed to country 1: 5 certificates with annex 1
  - Addressed to country 2: 6 certificates with Annex 1, 9 certificates with annexes 1 and 2

- **Medicinal product B:**
  - Addressed to country 1: 15 certificates with annex 1
  - Addressed to country 2: 6 certificates with annex 1

Fee payable using the standard procedure: **1 440 EURO** basic fee + (additional fee x 7)

- **320 EURO**
  - Basic fee
  - For the first set of 5 certificates for medicinal product A for country 1.

- **+ 160 EURO**
  - Additional fee
  - For the second set of 6 certificates for medicinal product A for country 2.

- **+ 160 EURO**
  - Additional fee
  - For the third set of maximum 6 out of 9 certificates for medicinal product A for country 2.

- **+ 160 EURO**
  - Additional fee
  - For the fourth set of 3 out of 9 certificates for medicinal product A for country 2.

- **+ 160 EURO**
  - Additional fee
  - For the fifth set of maximum 6 out of 15 certificates for medicinal product B for country 1.

- **+ 160 EURO**
  - Additional fee
  - For the sixth set of maximum 6 out of 15 certificates for medicinal product B for
Additional fee country 1.

+ 160 EURO

For the seventh set of 3 out of 15 certificates for medicinal product B for country 1.

Additional fee

+ 160 EURO

For the eighth set of 6 certificates for medicinal product B for country 2.

Fee payable using the urgent procedure: applying the same rationale as for the standard procedure, one basic fee and seven additional fees are payable: 960 EURO

Total fee = 960 EURO + (480 EURO* 7) = 4 320 EURO

The applicable fees to be paid using the standard procedure are represented in the flowchart below.